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ABSTRACT 
This thesis describes the development of serum and whole blood immunodiagnostic 
assays for Maedi-Visna virus (MVV). All previously described recombinant MVV 
ELISA assays utilised either the core p25 or transmembrane (TM) proteins alone, or 
combined, but as individual proteins. The p25 and TM genes of MVV were cloned 
individually into the pGEX-2T expression vector. Both proteins were expressed as a 
combined fusion protein in frame with glutathione S-transferase (GST). The purified 
recombinant antigens (GST -TM and GST -TM-p25) were used to develop a MVV 
ELISA. Sera from 46 positive and 46 negative sheep were tested using the GST -TM 
and GST -TM-'p25 ELISAs and a commercial p25 EIA kit. A two-graph receiver 
operating characteristic (TG-ROC) analysis program was used to interpret the data. 
The GST-TM-p25 ELISA was more sensitive than the commercial assay which is 
based on the p25 antigen alone and more specific than the GST -TM ELISA. The 
GST-TM-p25 ELISA showed a sensitivity and specificity of 100%. 
The human AIDS lentivirus transmembrane (TM) glycoprotein portion of the envelope 
viral protein has been identified as the antigen most consistently recognised by 
antibodies. There is suggestive evidence that the same applies to MVV as the GST -TM 
fusion protein, expressed in E. coli, has comparable sensitivity to the GST -TM-p25 
fusion protein, but lacks specificity. However, due to the hydrophobic nature of the 
MVV TM protein, purification of the expressed fusion protein required lengthy 
purification protocols. This was despite the fact that only a truncated version of the 
TM protein was expressed. This prompted investigating an alternative expression 
system that could possibly circumvent the above mentioned problems. The yeast 
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Pichia pastoris is known to be suitable for the high-level expression of heterologous 
proteins which are secreted into the culture supematant. These features made P. 
pastoris an attractive host for the expression of the hydrophobic TM protein of MVV. 
However, limited success was achieved as only low expression levels were obtained 
and detection and quantification was only accomplished by means of ELISA. 
Evaluation of the diagnostic performance of the P. pastoris expressed MVV TM-
polypeptide was performed using a panel of 36 confirmed negative and positive sera, 
and evaluated using a TG-ROC analysis programme, which yielded an equal Se and Sp 
of83%. 
The use of a novel rapid immunoassay system, which allows the detection of 
circulating antibodies in whole blood, has been investigated for use as a MVV 
diagnostic assay. The central feature of this immunoassay lies in a monoclonal antibody 
against a glycophorin epitope present on all sheep erythrocytes. A Fab'-peptide 
conjugate was constructed by coupling a synthetic peptide, corresponding to a 
sequence from MVV TM protein, to the hinge region of the Fab' fragment of the anti-
sheep erythrocyte antibody. Within the limited number of lO seronegative and lO 
seropositive samples the autologous red blood cell agglutination assay had a sensitivity 
of 90% and a specificity of 80%. Despite the limitations and difficulties encountered, 
the use of such rapid whole blood immunodiagnostic assays for MVV holds promise. 
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PREFACE 
The experimental work described in this thesis was carried out in the department of 
Virology, University of Natal, Medical School, Durban and the Natal Institute of 
Immunology, Pinetown, from January 1993 to December 1995 under the supervision 
of Dr. D.F. York (University of Natal) and Dr. lD. Conradie (Natal Institute of 
Immunology). 
These studies represent original work by the author and have not been submitted in any 
other form to another university. Work of other authors has been duly acknowledged 
in the text. 
(Christoffel Hendrik Boshofi) 
Date: 
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The ultimate aim of the [hero's J quest [is J neither release nor ecstasy for oneself, but 
the wisdom and the power to serve others. 
Joseph Campbell 
This thesis is dedicated 
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1.1 A BRIEF mSTORY 
The virus family Retroviridae IS divided into three subfamilies: Oncovirinae, 
Lentivirinae and Spumavirinae. The name lentivirus is derived from a group of 
infectious diseases associated with slow infections (Sigurdsson, 1954), distinguishing 
them from chronic diseases such as tuberculosis. Lentiviral disease in sheep was first 
described as a progressive pneumonia in South Africa by MitcheU in 1915 (pals son, 
1976). This was followed in 1923 by a report of severe chronic interstitial pneumonia 
of sheep in Montana that resulted in wasting and eventual death (Marsh, 1923). 
Maedi-Visna virus (MVV) was recognized as a pathogen of sheep as a result of an 
epidemic of a progressive pneumonia ("maedi"), accompanied in some cases by 
progressive paralysis. ("visna") which arose in Icelandic sheep flocks between 1939 and 
1952 (Sigurdardottir and Thormar, 1964). One hundred and fifty thousand animals 
were lost due to the disease and a further 650 000 destroyed in a successful attempt to 
control the disease (Sigurdsson, 1954). Transmission of the disease to healthy animals 
using tissue preparations from affected sheep was subsequently demonstrated 
(Sigurdsson et aI, 1957) and in 1967, a single virus was shown to be the causative 
agent of both maedi and visna, hence the term maedi-visna virus (Gudnadottir and 
Palsson, 1967). This virus was subsequently characterized as a nononcogenic, 
exogenous retrovirus of the Lentiviridae subfamily (Cutlip and Laird, 1976). MVV 
infection has now been recognized in numerous countries, including the Netherlands 
where it is known as zwoegerziekte (De Boer, 1970), Belgium (Biront and Deluyker, 
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1985), South Africa (Querat et al., 1990), the U.S.A., where it is sometimes known as 
ovine progressive pneumonia (Cutlip and Laird, 1976), Greece (Seimenis et al., 1985) 
and the U.K. (Dawson et al., 1990; Watt et al., 1990). In none of these countries has it 
yet had the same economic impact as in the Icelandic outbreak, although it is of 
importance in flocks with a high incidence of infection or in pedigree flocks. 
Lentiviruses have also been isolated from other animal species including the caprine 
arthritis-encephalitis virus (CAEV) of goats (Crawford et ai, 1980) and the equine 
infectious anaemia virus (EIA V) of horses (Vallee and Carre, 1904). Interest in 
lentiviruses was greatly increased when it was realized that the causative agents of 
human acquired immunodeficiency syndrome (AIDS) (lllV -1 and HIV -2) were also 
members of the lentivirus subfamily (Gonda et al., 1985; Sonigo et al., 1985). The 
search for AIDS animal models rapidly led to the isolation of simian immunodeficiency 
virus (SIV) of monkeys (Daniel et al., 1985), bovine immunodeficiency virus (BIV) of 
cattle (Gonda et al., 1988; Beatty, et al., 1992), and feline immunodeficiency virus 
(FIV) of cats (Pederson et al., 1987). This taxonomic group of viruses is based upon 
similarities in virion morphology, protein serological properties, genomic organization, 
nucleotide sequences, host cell specificities and patterns of pathogenesis. It is probable 
that more animallentiviruses will be identified in future. 
1.2 THE MAEDI-VISNA VIRUS GENOME 
MVV like other retroviruses, possesses a positive sense single-stranded RNA genome 
(Brahic et al., 1977), and replicates via a DNA intermediate (Haase and Varmus, 
1973). Each virion contains two RNA molecules and is therefore dimeric. The size of 
the MVV RNA genome varies from 9202 nucleotides for Icelandic strain 1514 (Sonigo 
2 
et al., 1985), 9203 nucleotides for a British isolate EVl (Sargan et al., 1991) to 9256 
nucleotides for SA-OMVV (Querat et al., 1990). Figure 1.1 shows the general 
organisation of the genome which is similar for most retroviruses. 
o 2 3 4 5 6 7 8 9 
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Figure 1.1 The MVV genome. The position of the U3, Rand U5 regions of the LTR 
and of the major open reading frames ofMVV are shown. Approximate nucleotide 
positions are indicated by the scale bar. T, tat; Rv, rev. 
The genome contains three major structural genes. From the 5' end the gag gene 
codes for the core proteins of the virus, pol codes for the RNAse H, protease, 
integrase and reverse transcriptase enzymes, while the env gene at the 3' end codes for 
the viral envelope glycoprotein. At both ends are the long terminal repeats (LTRs). 
These LTR sequences are divided into the U3, Rand U5 regions. They also contain 
the tRNA primer binding site, and a polypurine tract which acts as the initiation site for 
positive strand DNA synthesis. A well defined TATA box starts at nucleotide 438 and 
a CCAAT consensus sequence begins at bases 352 and 364 (Hess et al., 1985). Studies 
on the role of retroviral L TRs revealed that they contain target sequences that regulate 
the level of transcription and thereby viral replication in cells. Another feature of 
lentiviral genomic organization, is the presence of several additional open reading 
frames (ORFs) located between the pol and env genes and in the env region (Davis and 
Clements, 1988). These small ORFs encode proteins that regulate gene expression, 
3 
control production of infectious viral particles and are involved in the disease 
manifestation in vivo. These genes also show little nucleotide or amino acid homology 
among the different lentiviruses and may be one of the factors determining the species-
specificity of each lentivirus. An additional ORF, termed W, in SA-OMVV (Querat et 
al., 1990) has been shown to exist without any significant sequence homology to other 
lentiviral ORFs. However an open reading frame with sequence homology to lllV vif 
(Strebel et al., 1987) has been shown to be present in the MVV genome. 
1.3 MVV PROTEINS 
A general model of a lentivirus virion is presented in Figure 1.2. The virus has a 
diameter of approximately 100 nm with a lipid envelope enclosing an oblong core 
containing the diploid RNA genome. 






p9 and 7 (gag) Host Derived 
Proteins 
Figure 1.2 The major structural components ofMVV. 
gP41 
(transmembrane) 
The major precursor of the gag-encoded proteins is a non-glycosylated molecule of 55 
KDa (pr55gag) (Vigne et al., 1982) which is cleaved intracellularly to form the mature 
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proteins. The precursor polyprotein is transported to the site of virus assembly at the 
plasma membrane · where it is processed by the viral protease during budding into the 
native structural proteins found in virus particles. The core proteins of lentiviruses 
constitute the predominant protein components of the virus particle accounting for up 
to 90% of the virus protein. The p 16 matrix protein, located immediately beneath the 
envelope lipid bilayer is myristylated at its amino-terminus. The virus particle contains 
enough matrix protein to form a continuous monolayer, which is believed to be 
noncovalently associated with the envelope transmembrane (TM) protein. The major 
capsid shell protein is the most abundant protein in lentiviruses and is the major 
component of the core shell. The MVV major capsid protein has an approximate mass 
of 25 KDa and displays significant sequence homology within this protein group of 
viruses which is reflected by serological cross-reactivities. The third core protein of 
MVV is the highly basic ribonucleoprotein that is bound to the viral RNA, presumably 
to form a helical ribonucleoprotein complex. The ribonucleoprotein has a molecular 
mass of 14 KDa and is rich in lysine and arginine residues and contains a cys-his box, 
which is characteristic of various nucleic acid binding proteins and perhaps essential for 
reverse transcription and assembly (Meric and Goff, 1989). In summary, the order of 
gag proteins within the precursor is NH2-p 16-p25-p 14-COOH. 
The pol gene encodes the reverse transcriptase (RT) enzyme of which 5-10 copies are 
associated with the viral RNA in each virion. The MVV reverse transcriptase is Mg2+ 
dependent but has similar pH, substrate and temperature requirements to the Mn2+ 
reverse transcriptases of the type-C retroviruses (Lin and Thormar, 1970). By 
alignment with other retroviral pol sequences the conserved domains of visna virus pol, 
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corresponding to reverse transcriptase and endonuclease/integrase, are readily 
identified (McClure et al., 1987). However, production of the predicted protease and 
integrase proteins have not been directly demonstrated, although cleavage of the gag-
Pol precursor molecules (Vigne et al., 1982) and integration of the MVV genome 
(Vigne et a11985) suggest that both these functions may be present. 
The third major structural protein ofMVV has been shown to be the only glycosylated 
protein and is encoded by the env gene. These proteins are the primary targets for host 
immune responses and they mediate a number of important biological functions 
including binding to receptors and membrane fusion. The outer membrane glycoprotein 
is referred to as gp135 and the transmembrane glycoprotein (TM) as gp46. The outer 
membrane protein and the TM proteins are synthesized initially by translation of a 
spliced subgenomic mRNA to produce a polyprotein with the outer membrane protein 
as the amino-terminal component and the transmembrane as the carboxy-terminal 
component. 
Recently a general model has been proposed for the amino-terminal segment of TM 
protein of retroviruses (Gallaher et al., 1989). This scheme, presented in Figure 1.3~ 
demonstrates the conserved structural features proposed for the amino-terminal end of 











Figure 1.3 Model of the structure of the amino-terminal portion of a typicallentiviral 
TM protein adapted from Gallaher et al., 1989. 
Overall the TM protein is predicted to be a fibrous structure with a significant degree 
of sidedness~ all of the immunodominant sites are located at the apex and on one side 
of the molecule and the potential N-linked glycosylation sites on the other side. Several 
other common features are also evident in this model. Firstly, the laterally extended 
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amino terminus contains the fusion peptide, which presumably acts as a membrane 
insertional hairpin similar to the hydrophobic core of signal sequences. This is followed 
by an internally looping structure rich in serine and threonine that is postulated to 
interact with gp135, and by an ascending amphipathic helix that is a predicted T-cell 
epitope. This extended helix leads to the apex of the molecule containing an 
immunodominant epitope that is possibly stabilized by the characteristic conserved 
vicinal cysteines. The apex is followed by an extended a-helix containing the potential 
glycosylation sites. The descending helix terminates in a bend also rich in serine and 
threonine and is believed to interact with gp 13 5. This region is a highly charged region 
which can form an a-helix stabilized by multiple ion pairs. After a helix-bending 
tryptophan-rich region external to the lipid bilayer, there appears to be a hydrophobic 
membrane spanning a-helix that is terminated by a sharp turn just as the protein 
emerges from the lipid bilayer into the cell cytosol. 
In infected cells, the envelope polyprotein remains membrane associated, is rapidly 
glycosylated, and then assembled into the plasma membrane. The outer membrane and 
transmembrane proteins remain associated by noncovalent interactions, eventually 
forming the trimer complex found in mature virus particles. The outer membrane 
protein is loosely bound to the cell membrane or the viral envelope and is readily shed 
from the surface of the cell or virus. In contrast, the transmembrane protein is bound 
tightly, presumably traversing the lipid bilayer one or more times. The outer membrane 
protein of all three visna viruses shows areas of highly conserved sequence as well as 
areas of high variability (Sargan et al., 1991). Generally it is thought that variable 
residues are grouped at sites which are largely in hydrophilic and possibly external 
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positions in the Env protein (Ropp and Woods, 1981; Emini et aI., 1985) consistent 
with variations being fixed by immune selection. Selection acting upon antigenic 
variants ofvisna virus Env is well documented (Narayan et aI., 1978, 1981) and it is 
also indicated that the outer membrane protein of MVV is probably the major target 
for neutralization of virus infectivity by specific antisera (Scott et aI., 1979). The 
external part of the Env protein also contains 23 potential N-linked glycosylation sites 
(Querat et al., 1990). Sialic acid residues have been demonstrated on the surface of 
MVV particles (August et al., 1977), however the levels do not appear to be as high as 
in CAEV, and no clear functional role has been assigned to them. This is in contrast to 
CAEV where the residues are believed to have an important rol~ in protection of the 
virus from neutralizing antibodies, probably through steric hindrance (Ruso et al., 
1988). 
Of the proteins encoded by the small ORFs, the tat gene encodes a protein of 10 KDa 
which acts as a positive transactivator of viral transcription (Davis and Clements, 
1989). The rev gene encodes a 19 KDa polypeptide (Mazarin et aI., 1990) necessary 
for the cytoplasmic expression of the incompletely spliced env mRNA (Tiley et al., 
1990) and the vif gene encodes a 29 KDa protein detectable late in the lytic cycle hi 
vitro (Audoly et al., 1992) but it's function is still unclear. 
1.4 THE MVV LIFE CYCLE 
As with the other lentiviruses MVV characteristically displays very different patterns of 
transcription and replication in vitro and in vivo. In permissive cells in vitro, MVV 
causes extensive cytopathic effects (CPE) with formation of multinucleated giant cells 
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and the release of free infectious virus into the culture medium. Binding of MVV to a 
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Figure 1.4 Schematic presentation of a lentivirus replication cycle (Constantine, et al., 
1992. 
The first step in viral transcription and translation is reverse transcription of the viral 
single-stranded RNA (ssRNA) to form double-stranded DNA (dsDNA) (Sonigo et al., 
1985). The integration state of visna DNA is not clear. It has been claimed (Harris et 
al., 1984) that there was no detectable integration of MVV DNA into host 
chromosomal DNA during a lytic infection. However, integration has been reported 
(Vigne et aI., 1985) when infecting ovine foetal cornea cells but not choroid plexus 
fibroblasts. dsDNA serves as the template for transcription of viral genes, and for the 
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full-length genomic RNA which is eventually packaged into virions. The small, fully 
spliced transcripts are believed to encode the tat (Gourdou et al., 1989) and rev 
messages (Tiley et al., 1990). In MW infection, Rev appears to be at least dual-
functional; it can increase expression ofmRNAs from the LTR (Mazarin et aI., 1988) 
and acts to allow the expression of singly spliced env mRNAs in the cytoplasm (Tiley 
et al., 1990), the appearance of which is a critical event in progression of a lytic 
infection in vitro. Lytic infection leads to massive amplification of viral genomes with 
reports of cells containing in excess of 4000 copies of viral RNA (Brahic et al., 1977). 
The viral life cycle in vivo, however, is interrupted and this has important 
consequences for viral persistence. Virus cannot usually be recovered from tissue 
homogenates from infected animals, but if these are explanted, or if the tissues are 
maintained in culture with a permissive cell type, then infectious virus can be detected. 
This is consistent with a block on viral replication in vivo which is relieved under tissue 
culture conditions. Restricted viral RNA expression has been reported in monocytes 
obtained from the lateral ventricles of experimentally infected sheep (Peluso et al., 
1985) and restricted viral RNA levels have been demonstrated In 
monocyte/macrophage precursor cells in the bone marrow (Gendelman et al., 1985): 
Although much remains to be discovered about the restricted life cycle of MW in 
vivo, it is probable that interaction of cellular factors with the viral genome, and 
perhaps particularly the L TR, may play a critical role in limiting viral replication under 
the majority of in vivo conditions, and in relieving this block on the viral life cycle in 
tissue culture or when a latently infected cell is activated. 
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1.5 TROPISM OF MVV 
In vivo, MVV has been shown only to infect sheep and goats (Banks et al., 1983). It 
has been suggested (Houwers et al., 1989) that different sheep breeds may differ in 
their susceptibility to MVV but there are difficulties in distinguishing breed variations 
from inbred familial effects. Cells of the monocyte/macrophage lineage are the major 
target cell of MVV in vivo. Macrophages were shown to be infectable in vitro and 
macrophages from infected animals produced virus detectable by a co-cultivation assay 
with fibroblasts (Narayan et al., 1982). Clusters of infected macrophage precursors 
have been found in the bone marrow, which may act as a viral reservoir (Gendelman et 
al., 1985). Such a reservoir is essential for the continued survival of the virus within 
the host as blood monocytes and tissue macrophages are relatively short-lived. There 
are no convincing reports ofMVV infection oflymphocytes. 
1.6 GENETIC V ARIA TION 
Because the reverse transcriptase is prone to make errors when viral RNA is 
transcribed into DNA the mutation frequency of lentiviruses is quite high. Two 
different isolates of the same virus are rarely if ever completely identical in genetic 
sequence (Woodward et aI., 1994). This gives rise to alterations of the structure and 
antigenic properties of the virus and allows it to circumvent established immune 
responses (Clements et al., 1988). The result is antigenic variants that can elude 
immune surveillance and propagate even in the presence of fully competent host 
immune systems. Certain regions of the MVV genome are thought to be hypervariable, 
especially parts of the env gene (Narayan et aI., 1978). Lentivirus isolates recovered 
from different infected hosts may differ in overall nucleotide and deduced amino acid 
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sequences by as much as 15-20%. When strains of ovine lentiviruses from different 
parts of the world are compared, certain differences in biological characteristics are 
revealed. They show different growth in cell culture, some are more lytic than others 
(Querat et al., 1984) and it has also been shown that the original infecting virus type 
persists in the animal in coexistence with the new variants (Lutley et al., 1983). Studies 
showing virus mutation during the course of MVV infection have also been reported 
(Woodward et al., 1995). No link could, however, be established between the 
progression of the disease and the appearance of new variants. The disease spectrum 
also differs. Although interstitial pneumonia appears to be a common manifestation of 
ovine lentivirus infection in all countries, arthritis has only been reported in the U.S.A. 
(Carey and Dalziel, 1993). Clinical symptoms of the central nervous system (visna) 
have very rarely been seen outside Iceland (Zink and Johnson, 1994). Host genetic 
factors have also been shown to be important in determining the outcome of MVV 
infection although the influence of the virus strain phenotype cannot be ruled out. 
Consequently, it is likely that the outcome of a lentivirus infection depends on the 
interaction of both host and viral genes (de la Concha-Bermejillo et al., 1995). Genetic 
variation is a factor that has to be taken into account when selecting proteins to be 
used in diagnostic assays for MVV (see Chapter 2). 
1. 7 CHARACTERISTICS OF DISEASE 
In sheep, clinical disease caused by lentiviruses generally occurs only in adult animals, 
although in flocks with a high incidence of infection, yearlings may occasionally be 
affected. The extraordinarily long incubation period for MVV, noted during initial 
outbreak as one to three years or more (Sigurdsson, 1954) is followed by the onset of 
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disease symptoms with little subsequent regression and a generally progressive clinical 
course. The most common manifestation of lentiviral infection in sheep, regardless of 
geographical location, is chronic interstitial pneumonia (Marsh, 1923), characterized by 
thickened, often fibrotic, interalveolar septa and dense interstitial, perivascular and 
peribronchial infiltrates ofIymphocytes and macro phages (Cutlip et aI., 1985; Narayan 
and Clements, 1989; Bulgin, 1990). This explains the most commonly reported 
symptom of dyspnoea, which becomes particularly obvious if the affected animal is 
exercised. Post-mortem examination usually reveals lungs of two to four times the 
mass of normal lungs with decreased elasticity and a degree of fibrosis (Sigurdsson, 
1954). A large proportion of infected sheep also develop an indurative mastitis with 
intense periductal and interstitial lymphocytic infiltrates (Van der Molen et al., 1985). 
A small percentage of infected animals have arthritis, most often of the carpal joints, 
but occasionally involving other joints (Oliver et al., 1981). Neurological disease 
occurs only rarely in infected sheep, although during the Icelandic epizootic it was a 
relatively common manifestation in some flocks (Sigurdsson and Palsson, 1958). 
Wasting commonly accompanies the above disease syndromes and is frequently the 
initial indicator of infection. Such sheep are also immunocompromised and susceptible 
to secondary infections (Myer et al., 1988). In certain flocks, MVV is found as a co-
infection with Jaagsiekte retrovirus (JSRV), the causative agent of sheep pulmonary 
adenomatosis (payne et al., 1986). There have been tentative suggestions of in vivo 
synergism between the two retroviruses (DeMartini et al., 1987), based on accelerated 
development ofIesions when both viruses are present. 
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1.8 TRANSMISSION OF DISEASE 
The major route of transmission ofMVV is horizontal spread via respiratory route, and 
is probably exacerbated by close housing practices. In flocks in which the length of 
exposure of lambs to infected ewes was varied, there was a rising incidence of 
transmission with increasing periods of contact, rising to 81 % of lambs showing 
evidence of MVV infection when the flock was maintained intact for one year (De 
Boer et al., 1979). Horizontal transmission between adult sheep has also, been 
demonstrated for flocks maintained under standard management conditions (Houwers 
and Van der Molen, 1987). Concurrent MVV and sheep pulmonary adenomatosis 
(SPA) infection may lead to increased transmission of MVV infection (Dawson et al., 
1990), possibly as a consequence of the increased number of alveolar macrophages in 
SPA lungs contributing to an increase in MVV replication. There is little clear evidence 
for vertical transmission of MVV. Fifty lambs taken from their infected dams at birth 
(De Boer et al., 1979) all remained uninfected and no direct evidence for transplacental 
transmission could be demonstrated in the experiments of Sihvonen (1980). Unlike 
CAEV, in which it has been clearly demonstrated that maternal colustrum is a major 
infectious route (Ellis et al., 1983), such a mechanism has not been unequivocally 
demonstrated for MVV, despite the presence in ovine milk of cells from which virus 
can be intermittently isolated (Sihvonen, 1980). Sexual transmission of MVV has not 
been reported. There have also been no reports of an invertebrate vector, such as that 
implicated in transmission of El AV (Narayan and Clements, 1989). 
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1.9 HOST IMMUNE RESPONSES TO MVV 
Infection by lentiviruses results in both humoral (antibody-mediated) and cellular 
immune responses against viral antigens. Antibodies reacting with core, envelope, 
reverse transcriptase and other viral enzymatic and regulatory gene products are often 
found in infected hosts. Studies using experimentally infected sheep have demonstrated 
the generation of complement-fixing and neutralizing antibodies to MVV (Gudnadottir 
and Kristindottir, 1967). Although sheep develop antibodies which are described as 
neutralizing this is often a reflection of an in vitro assay technique involving prolonged 
prior incubation of MVV with serum and may not be an accurate representation of the 
in vivo activity of these immunoglobulins. Incubation of MVV with neutralizing 
antiserum for 15 minutes results in no detectable decrease in virus infectivity. A 
possible consequence of this in vivo is that the rate of virus binding to cells may be 
faster than the rate of neutralization (Kennedy-Stoskopf and Narayan, 1986). 
Neutralization in vitro has been shown to involve immunoglobulin of the IgG1 subclass 
and to be complement-independent (Kennedy-Stoskopf and Narayan, 1986). The viral 
proteins against which the humoral . response is mounted were determined in a 
longitudinal study of experimentally and naturally MVV-infected lambs. By 
immunoblotting it was shown that the first antibody to be generated was anti-p25 . 
followed by anti-gp135, anti-pl6 and anti-pl4 (Kajikawa et al., 1990), with some 
minor variation between sheep (Figure 1.5). 
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Figure 1.5 Serological ~~;ponse and ;ntig;nemia during a typical MVV infection 
(Houwers andNauta, 1989; Kajikawa et aI., 1990). 
Antibodies to the 11 KDa Rev protein have also been demonstrated in experimentally-
infected sheep (Vigne et al., 1990). However, the functional significance in vivo of the 
reactivity to each of these viral proteins is uncertain. It is unclear if antibodies to gp 13 5 
are protective, or if some may have a deleterious immunopathological effect. In 
CAEV, the titres of anti-gp135 in the synovia correlated directly with disease severity 
(Knowles et al., 1990) and in studies of lambs experimentally infected with MVV 
strains of different in vitro replication characteristics, the mean antibody titre to gp 13 5 
was three times higher in lambs which developed lymphoid interstitial pneumonia 
(Kajikawa et aI., 1990). Although this could suggest a pathological role for anti-gp135 
antibodies, it might also simply indicate that viruses which replicate to a higher titre in 
vivo generate more profound lesions, and coincidentally also stimulate a higher level of 
anti-gpl35 antibodies by the presence ofa greater antigenic dose. 
Little data is available on the cell-mediated response to MVV infection. An early cell-
mediated immune response to MW has been demonstrated one week following 
experimental intracerebral inoculation (Griffin et al., 1978) or four to six weeks 
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following respiratory tract infection (Sihvonen, 1981). This declines to control levels 
four to six weeks (Griffin et al., 1978) or eight to twelve weeks (Sihvonen, 1981) 
post-inoculation and is typical of the cell-mediated response to an acute infection. The 
available evidence therefore suggests that MVV persists in an infected animal despite 
an active immune response to the virus. The immune response appears to be incapable 
of clearing the virus in the early stages of infection, thereby permitting establishment of 
infection in the host tissues, and virus continues to be produced · subsequently despite 
the continuing specific immune response. 
1.10 DIAGNOSTIC ASSAYS 
Serological screening tests designed to detect lentiviral antibodies are many in number 
and variety, and are the most common approach for detecting infection. Since its first 
application by Engvall and Perlman (1971), the indirect enzyme-linked immunosorbent 
assay (i-ELISA) technique has been widely used for the serodiagnosis of various 
infectious diseases. For animal lentiviral infections, the i-ELISA has been applied to 
detect antibodies against caprine-arthritis encephalitis virus (CAEV) (Banks et al., 
1983), equine infectious anaemia virus (EIA V) (Suzuki et al., 1982) and maedi-visna 
virus (MVV) (Houwers et a!., 1982; Vitu et al., 1982). 
As a first step in performing the technique, a suitable preparation of the viral antigen is 
required to prevent undesirable background which might affect the sensitivity and 
specificity of the test (Voller et al., 1982). Houwers and Gielkens (1979) were the first 
to report the use of the conventional i-ELISA for MVV. Their antigen preparation 
required high speed centrifugation on a cushion of sucrose followed by ether 
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extraction. Ethyl ether is an organic solvent used to disrupt lipid viruses but is fairly 
ineffective in removing nonviral components (Philipson, 1967). In order to reduce the 
amount of cellular proteins interfering with the test, Vitu et al. (1982), stressed the 
importance of a more purified preparation of the viral antigen. They applied 
consecutive zonal centrifugation in density gradients such as sucrose to obtain good 
discrimination between positive and negative .serum samples. McGrath et al. (1978), 
indicated that retroviral activity is sensitive to the osmotic shock of suspension in 
sucrose gradients and that the conventional pelletlbanding technique had an adverse 
effect on the virus population. In order to reduce the problems associated with the 
production of MVV antigen a novel approach was taken by Simard and Briscoe 
(1990), by treating the virus particles with sodium dodecyl sulphate (SDS) instead of 
organic solvents. The SDS-treated antigen resulted in higher ELISA signals with 
positive serum and better discrimination between positive and negative serum samples 
from specific pathogen free sheep experimentally inoculated with the virus. 
A variety of different ELISAs are available and are classified as either indirect . , 
competitive, sandwich or capture assays. The most popular type of ELISA for the 
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Figure 1.6 Principle of the i-ELISA. 
In the i-ELISA, test s~rum is added to the solid phase containing the antigen and is 
incubated for a ~pecified time and at a particular temperature.' If anti-MVV antibodies 
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are present in the serum they will bind to the antigen on the solid phase. Following a 
wash step, conjugate (anti-sheep immunoglobulin labelled with an enzyme) is added 
and incubated. During this step, the anti-MVV antibody attached to the bound antigen 
will bind the conjugate. Another wash step removes excess conjugate, and substrate is 
added. During the subsequent incubation, the conjugate will modify the substrate to 
produce a colour. The i-ELISAs produce more colour as the unknown antibody 
concentration in the sample increases (Figure. 1.3). Conversely, with small amounts or 
an absence of antibody, smaller quantities of conjugate will bind, resulting in less 
substrate cleaved, less colour produced, and a lower O.D. value. Therefore, the O.D. 
value is directly proportional to antibody concentration in the sample. 
First generation assays based on viral lysate derived antigens are good tests but 
generally lack specificity. This is due to the presence of contaminating components 
derived from the cells in which the virus was propagated. If an unknown sample 
contains antibodies that react with these contaminating components, a false-positive 
reaction may occur. In addition, viral lysate tests are usually not 100% sensitive, 
probably because the high sample dilution needed to attain acceptable specificity 
eliminates the detection of small amounts of antibody. Also, contaminating cellular 
substances can occupy sites on the solid phase, thereby decreasing the space that is 
available for optimal quantities of the MVV antigen to attach. With less antigen 
attached to the solid support, less antibody can be detected and the indicator signal 
(colour) will be low. 
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Second and third generation assays utilise selected antigens. These precisely targeted 
portions of MVV are immunodominant epitopes that have a better chance of binding 
significant antibodies to MVV. In most cases these antigens are so called recombinant 
antigens. Recombinant antigens are produced when a portion of the MVV genome, 
which codes for a specific protein of interest, is inserted into a plasmid vector e.g. 
bacterial plasmids. Expression of the viral protein is under control of the plasmid 
promoter sequence which, when induced, results in the production of the gene product 
(antigen) by the recombinant plasmid. Since these recombinant plasmid containing cells 
can be grown easily in culture, they produce large quantities of the antigen. In addition, 
these antigens have the advantage of being easier to produce and purify. This results in 
the production of specific antigens that can be used to develop serologic tests with a 
high specificity (Reybum et a!., 1992; Kwang et a!., 1993; Keen et aI., 1995). 
All ELISA tests are easy to perform, but require careful adherence to procedures. Any 
deviation in incubation times, temperatures or volumes can result in dramatic changes 
in test results. Wash procedures must be thorough, and reagents must be prepared 
exactly in the same way each time. These prerequisites, therefore, confine ELISA type 
assays to a laboratory setting. 
1.11 RED CELL AGGLUTINATION AS AN IMMUNOASSAY SYSTEM 
All microparticulate antigens (e.g. bacteria, yeast, leukocytes and erythrocytes) may be 
agglutinated by antibodies to antigenic determinants on their surface and this 
phenomenon has been exploited widely in the study of cell and micro-organism surface 
antigens and in the detection of antibodies. Tests employing agglutination as the 
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indicator system have been used for diagnosing infectious diseases for many years 
because they are generally very sensitive. However, specificity is sometimes 
compromised. The ability of red blood cells (RBCs) to be agglutinated, or cross-linked, 
has been used to monitor antigen-antibody interactions (reviewed by Coombs 1981, 
1987, 1989). When antigens are bound without specific attachment (passively adsorbed 
onto carriers) the technique is referred to as passive agglutination. If RBCs are used as 
the carrier system, the assay is called a passive haemagglutination assay. During the 
agglutination reaction, a lattice network is formed between the antigen-coated particles 
and the antibody, as antibody in the sample reacts in the system. 
This reaction brings about the clumping (agglutination) of particles (Figure 1.7). The 
agglutination is visible with the naked eye. 
Figure 1. 7 Formation of the lattice network seen as visible agglutination. 
Protein antigens can be adsorbed onto red cells by prior treatment of the cells with 
tannic acid (Boyden, 1951). One recent example was a test for HIV-1 antibodies which 
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used sheep red cells coated with a recombinant antigen of the virus (Vasudevachari et 
al., 1989). Cross-linking reagents such as bis-diazotized-benzidine (BDB) (Stavitsky 
and Arquilla, 1958) have also been used with success. 
One possible problem with agglutination assays is the phenomenon of prozone 
reactions. Prozone refers to the inhibition of agglutination when excess antibody is 
present, thereby preventing the optimal combination of antibody and antigen. In this 
case, the lattice network may not be sufficient to produce a visible agglutination; the 
high concentration of antibody binds to antigenic sites in such a manner that cross-
linking of the complexes cannot occur (Figure 1.8). 
Figure 1.8 Absence of agglutination due to prozone (antibody excess). 
This may result in a false-negative reaction (no agglutination) when higher 
concentrations of reacting antibody are present in the serum. In the case of antibody 
excess and the occurrence of the prozone phenomenon, antibody in the sample can be 
detected if the sample is diluted and retested. Dilution of the serum decreases the 
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concentration of antibody to a point where the optimal concentration of antigen and 
antibody occurs, and agglutination proceeds. 
Another disadvantage is that coupled red cells are unstable and it is usually necessary 
to prepare fresh red cell labelled antigen/antibody reagent after 2-3 weeks storage at 
4°C (Siddle et aI., 1984). To increase red cell stability, further chemical treatment with 
. glutaraldehyde is often required (Cranage et al., 1983a). Such treatment can alter cell 
membrane fluidity and thus decrease surface contact between erythrocytes which 
results in weaker agglutination. A sample pre-treatment step is also often required to 
reduce non-specific reactions. If red cells from a different species to that of the sample 
are used, the sample can be pre-adsorbed with uncoupled erythrocytes to remove 
sample constituents which may cause non-specific agglutination (Cranage et aI., 
1983b). 
Agglutination assays are easy to perform and require no wash procedures. The sole 
requirement is an initial dilution of serum, addition of coated red cells, mixing and 
incubation, usually at room temperature. However, the problems as mentioned above, 
have limited its widespread use. 
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1.12 ENDOGENOUS ERYTHROCYTE AGGLUTINATION ASSAYS 
1.12.1 Principle 
Rapid diagnostic assays were traditionally based on particle agglutination (Francis et 
a!., 1988), haemagglutination (Welsh et aI., 1987) and immunoblotting (Santos et al., 
1987). All these assays were comparable in terms of their sensitivity with enzyme 
immunoassays (EIA) but required the use of serum rather than whole blood. The quest 
for simpler methods led to the development of an autologous whole blood 
agglutination assay as reported by Hillyard et al., in a patent application in 1988 and 
published later (Hillyard et a!., 1990). This patent described the use of a non-
agglutinating anti-red cell mono clonal antibody raised against human glycophorin 
which is present on essentially all human erythrocytes (Rylatt et al., 1990). The 
principle feature of the whole blood immunoassay system lies in a bispecific reagent 
consisting of a monoclonal antibody against red cells chemically coupled to an antigen 
(Figure 1.9). Upon addition to whole blood from the individual being tested, the 
bispecific reagent effectively coats the erythrocytes with antigen. In the presence of 
specifically reacting antibodies to the coupled antigen, cross-linking of the erythrocytes 













Such an assay system was used for the detection of antibodies to the human 
immunodeficiency virus, mV-l (Kemp et al., 1988), where the conjugate consisted of 
a peptide, representing an immunodominant portion of the virus, coupled to the intact 
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anti-red cell monoclonal antibody. The test detected 42 out of 43 seropositive patients 
and gave one false positive response out of 874 normal blood donors. 
1.12.2 Advantages over other immunoassays 
The endogenous erythrocyte test format has three major advantages. 
1. The test is carried out using whole blood with minimal sample handling. 
2. Performance of the assay requires no special training or equipment. 
3. Results can be obtained within two minutes. 
Most immunoassays are characterized by the necessity to separate red cells from serum 
or plasma. This usually requires the use of a centrifuge restricting the use of the test in 
the field. Thus the applicability of the autologous red blood cell agglutination assay in 
the field may be considered one of its main advantages. Furthermore, the simplicity of 
the assay - no sample pre-dilution or washing steps are necessary - means that highly 
trained staff are not required to perform the test. 
1.13 THE PREPARATION OF ANTIBODY CONJUGATES 
1.13.1 MonocIonal antibodies 
The advent of monoclonal antibodies (Kohler and Milstein, 1975) opened 
opportunities for new assay configurations. This technique allowed for the growth of 
clonal cell populations secreting antibodies of defined specificity. The splenocytes of 
the immunized animal are allowed to fuse with immortal myeloma cells (Figure 1.10). 
These myeloma cells are derived from a mutant cell line of tumour B-Iymphocytes 
unable to produce immunoglobulins. The resultant hybrid cells, or hybridomas, . are 
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maintained in vitro and will coritinuously secrete monoclonal antibodies with a defined 
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F;igure 1.10 The general procedure of monoclonal antibody production in mice 
(Campbell, 1987). 
The immortal nature of the myeloma cells gives hybrid cells the ability to multiply 
indefinitely in culture. The hybridomas are grown on a selective growth medium 
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known as hypoxanthine-aminopterin-thymidine (HAT) medium. Aminopterin is an 
inhibitor that blocks the normal biosynthetic pathways by which nucleotides are made. 
The myeloma cells used for hybridization lack a purine salvage enzyme, hypoxanthine 
phosphoribosyl transferase (HPRT). The absence of HPRT results in a defect of the 
alternate pathway to synthesize nucleic acids, so that the cells die in HAT medium. The 
fused cells survive in HAT medium, whereas the unfusedspleen and myeloma cells die 
in HAT medium. Therefore, the B-Iymphocytes provide the HPRT enzyme for 
metabolic bypass, and the myeloma cells the ability to grow indefinitely in culture 
(Campbell, 1987). 
1.13.2 Structure and properties of an immunoglobulin molecule 
Methods used in the construction of antibody conjugates, and their applications, have 
been greatly expanded by the availability of highly specific and purified monoclonal 
antibodies. Underlying all this is understanding and utilising the different properties of 
the antibody molecule. The general structure of antibodies was elucidated by several 
key studies (porter, 1959; Edelman et aI., 1961, 1962, 1963, 1968). Immunoglobulin 
molecules are glycoproteins, each containing four polypeptide chains, two identical 
heavy chains (H), and two identical light chains CL) (Figure 1.11). 
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Figure 1.11 The immunoglobulin class G molecule 
The amino terminal ends of each polypeptide chain show considerable variation in their 
amino acid composition and are referred to as the variable (V) regions to distinguish 
them from the relatively constant (C) regions. The chains are held together by a 
combination of non covalent interactions and covalent interchain disulphide bonds, 
forming a bilateral symmetric structure. The V regions of the heavy (H) and light (L) 
chains comprise the antigen-binding sites of the immunoglobulin (Ig) molecules. Each 
Ig monomer contains two antigen-binding sites and is therefore bivalent. The hinge 
region is the area of the H chains which is held together by disulphide bonds. This 
flexible hinge region allows the distance between the two antigen-binding sites to vary. 
The portion of the antibody below the hinge region is known as the Fc region and is 
responsible for the effector functions (e.g. complement fixation) of the antibody 
molecule. The five primary classes of immunoglobulins are IgG, IgM, IgD, IgA and 
19E and are distinguished by differences in the heavy chain. IgG, a monomer, is the 
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predominant Ig class present in human serum, and it is the antibody produced in the 
secondary immune response to an antigen. The subclass of an Ig molecule is also 
determined by its heavy chain type. The constant region of the heavy chain of each IgG 
subclass is an isotype that is present in all members of a particular species. Mouse 
derived monoclonal antibodies can be distinguished as four subclasses of IgG: IgGl, 
IgG2a, IgG2b, and IgG3. Because of its relative abundance and excellent specificity 
toward antigens, IgG is the preferred antibody class used in immunological research 
and clinical diagnostics. 
The immunoglobulin molecule can be selectively cleaved into fragments, each having 
discrete activities, by the enzymes papain and pepsin (Parham eta/., 1982; Mage and 
Lamoyi, 1987; Beale, 1987) (Figure 1.11). Papain is a non-specific, thiol-
endopeptidase that has a sulfhydryl group in the active site, which must be in the 
reduced form for activity. When IgG molecules are incubated with papain in the 
presence of a reducing agent, one or more peptide bonds in the hinge region are 
cleaved, producing three fragments of similar size: two Fab' fragments and one Fc 
fragment (Coulter and Harris, 1983). Papain is primarily used to generate Fab' 
fragments, but it can also be used to generate F(ab)2 fragments (Goding, 1983). To 
prepare F(ab)2 fragments, the papain is first activated with cysteine. The excess 
cysteine is then removed by gel filtration. If no cysteine is present during papain 
digestion, F(ab)2 fragments can be generated. Pepsin, on the other hand, is a non-
specific endopeptidase that is active only at acid pH. It is irreversibly denatured at 
neutral or alkaline pH. Digestion by the enzyme pepsin normally produces one F(ab)2 
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fragment and numerous small peptides of the Fc portion (parham et al., 1982). The 
resulting F(ab)2 fragment is thus composed of two disulphide-connected Fab' units. 
1.13.3 Intact antibody-protein conjugates 
In general, intact antibody can be used to produce active conjugates provided the 
appropriate cross-linking reagents and reaction conditions are chosen. However, the 
use of intact antibody also has some drawbacks. One of the main disadvantages 
associated with cross-linking whole antibodies is inactivation of the antigen binding 
portion of the antibody by random coupling. Secondly, the hydrophobicity of the Fc 
region is undesirable in immunoassay systems as it is commonly implicated in non-
specific binding (Gosling, 1990). It is for these reasons that many conjugation methods 
now employ antibody Fab' fragments, where the hinge. sulthydryls are an ideal coupling 
target distal to the antigen binding region. Also, the Fc region is removed prior to 
coupling with this reaction strategy. 
1.13.4 Antibody fragment-protein conjugates 
In order to produce active bispecific antibody a region specific coupling method which 
allows binding distal to the Fab' region is necessary. Brennan and colleagues (1985) 
reported a method which fulfilled these requirements. The method involved the use of 
5,5' -dithiobis(2-nitrobenzoic acid) (DTNB), a chemical compound which reacts 
quantitatively with free thiols to produce the 2-nitro-5-thiobenzoate (TNB) anion, 
which has a characteristic orange colour (ElIman, 1959), and TNB coupled to the 
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Figure 1.12 The reaction ofDTNB with thiol groups. One mole of free thiol produces 
one mole ofTNB2-. 
A mouse monoc1onal antibody directed against a red blood cell epitope can be digested 
to produce F(ab)2 fragments. The F(ab)2 inter-heavy chain disulphides are reduced with 
2-mercaptoethylamine (Figure 1.13), in the presence of EDT A to prevent heavy metal 
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Figure 1.13 Flow diagram for the preparation of Fab'-peptide conjugate. Intact anti-
sheep erythrocyte antibody is digested with papain to produce F(ab)2 fragments, which 
are subsequently reduced with 2-mercaptoethylamine to Fab' fragments. The Fab' 
fragments are then stabilised with DTNB and the TNB substituted with reduced 
synthetic peptide. Any remaining free sulfhydryls were alkylated with iodoacetamide 
resulting in a stable Fab'-peptide conjugate. 
Three TNB per Fab' are produced, corresponding to the three thiols in the hinge region 
of IgG1. The resulting molecule, Fab'-TNB, is stable and can subsequently be allowed 
to react with an immunodominant peptide containing free reduced sulfhydryls (Figure 
1.13). The reaction is stopped by alkylating the free sulfhydryls before purifying the 
Fab'-peptide conjugate. 
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1.14 AIMS OF TmS STUDY 
The broad aim of this study was · to clone and express antigenic epitopes from Maedi-
Visna virus (MVV) and investigate their use . in immunodiagnostic assays. The 
successful development of sensitive diagnostic methods for human AIDS lentiviruses 
stimulated the search for a reliable, sensitive and accountable ELISA for MVV. Thus, 
the initial step was to express such selected antigenic regions of MVV in a prokaryotic 
expression system. The diagnostic performance of each recombinant antigen was then 
evaluated by comparison with pathological evidence (Chapter 2). 
Although prokaryotic expression systems are known to be versatile vehicles for the 
cloning and expression of foreign DNA, certain limitations do exist. In the past few 
years, many of these limitations were addressed by the construction of various 
eukaryotic gene expression systems. The methylotrophic yeast, Pichia pastoris, is · 
known for high-level gene expression and its potential use as an alternative expression 
system for MVV epitopes, was investigated (Chapter 3). 
The urgent need for simpler test methods has been highlighted by reports describing 
the development of rapid serological assays. Such an assay, performed on whole blood 
samples with a visible result in two minutes, was reported recently. This assay system 
has led to the development of diagnostic tests for a variety of diseases of both medical 
and veterinary importance. The use of such a whole blood diagnostic assay for the 
detection ofMVV infection, was investigated in the present study (Chapter 4). 
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CHAPTER 2 
CLONING AND EXPRESSION OF A SINGLE FUSION 
TRANSMEMBRANE':'CORE p25 RECOMBINANT PROTEIN FOR 
USE IN A MVV ELISA 
2.1 INTRODUCTION 
Since MVV poses a world-wide threat to commercial sheep farming (pritchard and 
Dawson, 1987; Cutlip et al., 1992), various techniques have been developed for its 
serologic diagnosis. These include agar gel immunodiffusion (AGID) (Cutlip et al., 
1977), indirect enzyme-linked immunosorbent assay (i-ELISA) (Houwers et al., 1982), 
ELISA based on a double antibody sandwich blocking procedure (Houwers and 
Schaake, 1987) and Western blot analysis (Houwers and Nauta, 1989). 
Most current MVV antibody tests are based on an EIA format, with screening tests 
usually performed in a 96-well EIA plate. Recombinant viral proteins have proved to 
be of great value in the serodiagnosis of MVV. Studies using either the core p25 or 
TM proteins have been used in screening assays (Reyburn et al., 1992; Kwang et al., 
1993; Keene et al., 1995). However, these studies have shown that both the core p25 
and TM epitopes are necessary to produce a sensitive and specific screening assay. 
This is due to the fact that the immune response tends to shift during the course of the 
disease from initially being p25 specific to being predominantly TM specific towards 
the end of the disease (Houwers and Nauta, 1989; Kajikawa et al., 1990) (see Figure 
1.5). 
In this chapter, the following are described; i) cloning of selected fragments of MVV 
p25 and TM proteins in the same expression cassette, ii) expression of these two 
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distinct epitopes as a single fusion protein in Escherichia coli, and, iii) purification and 
use of this fusion protein in an MVV antibody detection ELISA. The cut-off value of 
this assay was determined using a two-graph receiver operating characteristic method 
(TG-ROC) recently reported by Greiner et al. (1995). The optimised assays using the 
GST -TM, GST -TM-p25 and a commercial assay based on the p25 protein were tested 
against 46 MVV positive and 46 MVV negative sheep sera. 
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2.2 MATERIALS AND METHODS 
2.2.1 Polymerase Chain Reaction (PCR) 
The genes coding for the TM and p25 proteins ofMVV (obtained from a clone of SA-
OMVV provided by R. Vigne, Marseilles, France) were amplified as a 273-bp TM and 
748-bp p25 DNA fragment by PCR (Boshoff et al., 1996a). The 5' primers were 
designed to amplify the TM and p25 regions so that they respectively contained 
BamH 1 and EcoRI restriction sites to facilitate cloning of the amplicons (Table 2.1). 
The sequences of the 3' primers are also given in Table 2.1 . 
Table 2.1 
The nucleotide sequences and genomic locations of PCR primer pairs used to PCR 
amplify the MVV p25 and transmembrane C!M2 genes. 
Primer Sequence (5' - 3') Gene and location* 
" 'p25'§pri~~~"""'TCE'ccE'GAA" TIE'GTA"TGA"AAG"AAG" GGC··TAC····· ··· ···········g~i·(737·~75·6)·· ·· · · · .. · .. ·· 
AC 
p25 3' primer TCC CCC GAA TIC TCC TIC TGA TCC TAC GTC 
TM 5' primer TCC CCC GGA TCC GAA GCT AT A GTC GAT AGA 
TM 3' primer TCC CCC GGA TCC TGC CTC GTG TTG CTC TAT 
* See Querat et al. 1990. 
gag (1485-1468) 
env (8084-810 1) 
env (8357-8340) 
The PCR mix contained 10 mM Tris-HCI (pH 8.3), 50 mM KCI, 2.5 mM MgCI, 
0.01 % gelatin, 200 IlM of each dNTP, 40 pmol of each of the TM and p25 primers and 
20 ng of template DNA in a final volume of 100Jll. The mixture was heated to 94°C 
for 5 min in a Perkin-Elmer 9600 thermocycler, cooled on ice for a further 5 min and 
2.5 U ofTaq DNA polymerase (promega, Madison, WI) was added. The samples were 
amplified for 25 cycles. Each cycle consisted of a denaturation step at 94°C for 30 sec 
followed by annealing at 55°C for 30 sec and extension at 72°C for 30 sec. The final 
extension step was at 72°C for 5 min to allow complete extension of all DNA 
products. Verification of the correct size of each amplicon was established by running 
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each completed PCR reaction product through 2% (w/v) agarose (Sigma) containing 
0.005% ethidium bromide in TAE-buffer 
(40 mM Tris, 20 mM acetic acid and 50 mM EDT A, pH 7.2) as compared to a 
standard DNA marker vm (Boehringer Mannheim) and visualised by using ultraviolet 
transillumination (Sambrook et al., 1990). These PCR products were purified (Spin 
kit, Qiagen, Chatsworth, CA, U.S.A.) and subsequently digested with either BamHl or 
EcoRl restriction enzymes. 
2.2.2 Restriction digestion and dephosphorylation of pGEX vector DNA 
The pGEX vector DNA (pharmacia, Uppsala, Sweden) was linearized by digesting 
maximally 5 Ilg of DNA in a total volume of 50 III with 20 units of the appropriate 
restriction enzyme for 5 h at 37°C. The One-Phor-AlI buffer PLUS™ (OPA) from 
Pharmacia was used since it is compatible with virtually all restriction enzymes and 
many modifying enzymes. (See Appendix 1 for the composition of OPA.) A small 
aliquot of the reaction mixture was examined by agarose gel electrophoresis as 
described above, to ensure that the pGEX DNA had been digested to completion. 
Since the pGEX DNA was digested with a single restriction enzyme, the 5' phosphate 
groups had to be removed prior to ligation, to prevent recircularization of the vector. 
Calf intestinal alkaline phosphatase (pharmacia) was diluted in OPA buffer before a 
total of 0.1 units (1-2 III of diluted enzyme) was added to the digested pGEX vector 
DNA. Dephosphorylation took place for 30 min at 37°C before heat-inactivation at 
85°C for 15 min. The vector DNA was subsequently purified by ethanol precipitation. 
Briefly, an equal volume of phenol-chloroform-isopropanol 25:24:1 (v/v) (Sigma) was 
added to the aqueous sample, mixed by vortexing for 1 min and then centrifuged at 
12000 x g for 5 min to separate the phases. The upper aqueous phase was 
40 
subsequently transferred to a clean tube to which an equal volume of chloroform-
isopropanol 24: 1 (v/v) was added. Mixing and centrifugation was repeated as 
described above to separate the phases. The upper aqueous phase was then transferred 
to a clean tube to which 0.1 volume of 3 M sodium acetate (pH 5.4) and 2.5 volumes 
of absolute ethanol (Merck) was added. The solution was carefully mixed and kept at -
20°C for 15 min. The vector DNA was pelleted by centrifugation at 4°C for 15 min at 
12000 x g before being washed with 1 ml 70% ethano1. The subsequent DNA pellet 
was allowed to air dry at 37°C before being dissolved in 20 J-lI of TE buffer (10 mM 
Tris-HCI pH 8.0, 1 mM EDTA). The pGEX DNA was stored at -20°C for later use. 
2.2.3 Ligation of insert DNA to pGEX DNA 
The linearized pGEX vector DNA and insert DNA were mixed at a vector to insert 
molar ratio of 1: 5. The molar number of ends of linear DNA were calculated using the 
following formula where one O.D. unit at 260 nm was equivalent to 50 J-lg/mllinear 
double-stranded pGEX vector DNA consisting of 4900 base pairs. 
moles of ends = 2 x (g of DNA) + [(number of bp) x (649 DaItons/bp)] 
The final ligation reaction mix consisted of not more than 200 ng of DNA and 
contained 1 mM ATP and 5 units of FPLCpurelM T4 DNA ligase (pharmacia} 
Incubation was overnight at 16°C. The reaction was terminated by heating the ligation 
mixture at 65°C for 10 min. Ligated DNA was used to transform competent cells. 
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2.2.4 Transformation of competent cells with pGEX DNA 
The protocol used was based on the procedure described by Hanahan (1985). The 
composition of buffers and media used are described in Appendix 1. A single colony of 
the Escherichia coli JM105 strain was picked from a SOB agar plate and incubated in 
10 ml of SOB medium at 37°C until the cells reached mid-logarithmic growth phase 
(~60 = 0.35-0.40). The cells were harvested by centrifugation (1000 x g, 15 min, 4°C) 
and resuspended in standard transformation buffer (TFB) 
(see appendix 1), using 1/3 of the original cell culture volume. The cell culture was 
vortexed and incubated on ice for 15 min. The cells were centrifuged, as described 
above, before being resuspended in TFB using 1/25 of the original cell culture volume. 
This concentration gives a standard unit transformation volume. The competent E. coli 
JM105 cells {lOO J.lI) were aliquoted in polypropylene tubes. For transformation, 
pGEX DNA in maximally 20 J.lI {l0 - 50 ng) was added to the competent cells and 
incubated on ice for 30 min. The cells were heat-shocked by placing the tubes in a 
42°C water bath for 45 sec before being chilled by returning the tubes immediately to 
ice. To this, sac medium (800 J.lI) was added and incubated at 37°C' for 60 min with 
moderate agitation. Incubated cells were spread onto 2 x YT-G agar plates (Appendix 
1), containing 100 J.lg/ml ampicillin and incubated overnight at 37°C. 
2.2.5 Small-scale isolation of pGEX DNA 
The alkaline lysis plasmid mini-prep method allows for the rapid isolation of small 
amounts of plasmid DNA without the need for column purification or banding in CsCI 
gradients (Krieg and Melton, 1984). The procedure takes advantage of the rapid 
alkaline denaturation of plasmid and chromosomal DNA and the selective renaturation 
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of plasmid DNA following neutralization of the solution. Colonies appearing after 
incubation as described above, were picked and grown overnight in 1.5 ml 2 x YT-G 
medium containing 1 00 ~g/ml ampicillin. Cells were harvested by centrifugation 
(12000 x g, 15 min, 4°C) and resuspended in 200 ~l solution I (Appendix 1) by 
vortexing vigorously. Solution II (Appendix 1) (200 ~l) was added and mixed by 
inverting the tube several times. The solution was incubated for 5 min at room 
temperature. Solution lIT (Appendix 1) (200 ~l) was added, mixed by inverting the 
tube several times. The solution was incubated on ice for 5 min, centrifuged (12000 x 
g, 5 min, 4°C) and the DNA containing supematant transferred to a clean tube. 
Ambient-temperature isopropanol (0.7 volume) was added and carefully but 
thoroughly mixed by inverting the tube. The plasmid DNA was pelleted by 
centrifugation (12000 x g, 10 min, RT), the supematant decanted and the DNA 
resuspended in 200 ~l TE buffer. Using this protocol, 1-4 ~g of plasmid DNA can be 
obtained from 1.5 ml of culture. To verify the presence of the correct sized insert, 2 JlI 
(± 200 ng DNA) was digested with the appropriate restriction enzyme (10 units) for 1 
h at 37°C and analysed by agarose gel electrophoresis as described in Section 2.2.1. 
2.2.6 Sequencing of cloned fragments 
The plasmid containing the cloned fragments, pGEX-MVVITM-p25, was purified 
using the Qiagen midi prep method, concentrated using a Microcon-30 filter (Arnicon, 
Beverly, U.S.A.), and sequenced using an autoread sequencing kit (pharmacia Biotech) 
with a few modifications. One microgram per kilobase of plasmid/insert DNA was 
sequenced using the pGEX 5' and 3' sequencing primers (2 pmol) and a Fluoro-dATP 
mix (pharmacia Biotech). Sequencing was performed using the Automated Laser 
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Fluorescent (ALF) DNA sequencer. Sequencing data was analyzed using the DNASIS 
software (Hitachi Software Engineering, U.S.A.) and Genbank data bank sequences. 
Internal primers were used to confirm the sequence in both directions. 
2.2.7 Expression and purification of fusion proteins 
All recombinant proteins were expressed in E. coli JM105 as a fusion protein linked to 
glutathione S-transferase (GST) (Smith and Johnson, 1988). Expression and 
purification of the recombinant proteins was essentially as described by Grieco et al. 
(1992). Briefly, an overnight culture of transformed E. coli was diluted 1:10 in Luria-
broth containing 50 ~g/ml ampicillin and incubated at 37°C until the culture reached an 
O.D.600 of 0.6-0.8. Isopropyl ~-D thiogalactoside (IPTG) (Sigma) was added to a 
final concentration of 0.1 mM to induce the expression of the recombinant proteins. 
The cultures were incubated at 20°C for 3 h, centrifuged (5000 x g, 10 min, 4°C) the 
supernatant discarded, and the pellet resuspended in 1120 the original culture volume in 
PBS (0.15 M NaCI, 0.05 M phosphate) containing 0.2% N-Iauroylsarcosine (Sigma), 2 
mM EDT A and 1 mM triethanolamine. The solution was freeze-thawed twice and 
sonicated (Virtis instrument) on ice for five lOs, 140 Watt, pulses with 1 min intervals. 
Triton X-lOO was added to a final concentration of 1% before centrifugation (10 000 x 
g, 30 min, 4°C). The supernatant was added to a 50% preswol1en slurry of glutathione 
agarose beads (Sigma). The suspension was gently agitated for 3 min and washed three 
times with 50 ml ice-cold PBS. The fusion proteins were eluted with 1 m1 elution 
buffer (50 mM Tris-HCI, pH 8.0, 10 mM reduced glutathione) and gentle mixing for 2 
min. The elution step was repeated a total of 4 times and the eluants pooled. 
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2.2.8 Electrophoresis of fusion proteins 
The purity and relative molecular size of the recombinant proteins were analyzed by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) according 
to the method of Laemmli (1970). This one-dimensional electrophoretic analysis was 
carried out in a 0.1% SDS-containing 12.5% polyacrylamide gel with a 5% stacking 
gel in a Bio-Rad slab-gel apparatus. The affinity purified proteins were suspended in an 
equal volume of 0.1 M Tris-HCI buffer, pH 6.8, containing 2% (w/v) SDS, 20% (w/v) 
sucrose, 1% (v/v) 2-mercaptoethanol, and 0.001% (w/v) bromophenol blue and 
heated in a 100eC water bath for 5 min. Samples (20 Ill) were applied to the sample 
wells and subjected to electrophoresis at 50 mA/gel until the bromophenol blue 
migrated to 2 cm from the bottom of the gel. Proteins were stained overnight with 
0.2% Coomassie Blue, in 45% methanol and 10% acetic acid. The gel was 
subsequently washed in a destaining solution consisting of methanol, · acetic acid and 
water in a ratio of 5: 1 :5. 
2.2.9 Western blot analysis of fusion proteins 
The separated fusion proteins were electrophoretically transferred from the gels onto 
nitrocellulose membranes (Schleicher and Schuell, Keene, u.K.) as described 
previously by Zanoni et al. (1989). The transfer was performed at 100 V (constant 
voltage) for 1 h using a trans-blot electrophoretic transfer cell (Bio-Rad). The blotting 
buffer consisted of 20 mM Tris-HCI (PH 8.3), 150 mM glycine and 20% (v/v) 
methanol. After blotting, the membranes were equilibrated in TBS [50 mM Tris-HCI, 
150 mM NaCl, pH 8.0] for 10 min and blocked for 1 h in 5% (w/v) skimmed milk in 
Tris-buffered saline containing 0.05% (v/v) Tween 20. The membrane was washed in 
Tris-buffered saline before being incubated with a hyperimmune MVV positive serum 
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diluted 111000 in Tris-buffered saline containing 0.05% (v/v) Tween 20 for 4 h on a 
rocking platform at room temperature. The membrane was washed (3 x 10 min) with 
TBS, and incubated for 4 h with protein G peroxidase conjugate (Zymed, CA, U.S.A.) 
.. diluted 112000 in Tris-bufferedsaline containing 0.05% (v/v) Tween 20 at room 
temperature. The membrane was washed (3 x 10 min) in TBS and developed in a 
freshly prepared developing solution of 60 mg 4-chloro-1-naphtol (Bio-Rad) in 20 m1 
methanol to which 100 m1 Tris-buffered saline containing 60 ,.d of 30% hydrogen 
peroxide was added. 
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2.2.10 Detection of antibodies 
The ELISA procedures were essentially as described by Kwang and workers (1993, 
1995). Purified recombinant GST-TM and GST-TM-P25 fusion proteins were diluted 
1 in 200 in 0.1 M sodium bicarbonate buffer, pH 9.6, and passively adsorbed onto the 
surface of 96-well microtitre plates (Greiner, Germany) (Wade-Evans et al., 1993). 
Following an overnight incubation, at room temperature, the plates were washed three 
times with washing buffer [50 mM Tris-HCI, 150 mM NaCI, pH 8.0 containing 0.05% 
(v/v) Tween 20]. Glutathione S-transferase (GST) extracted from E. coli transformed 
with pGEX-2T served as the negative control antigen in the ELISA. The plates were 
dried under vacuum and stored at 4°C. On the day of use, plates were blocked for 1 h 
at 37°C with 200 J..l.I of a 5% (w/v) skimmed milk solution in washing buffer. Test sera 
were added (100 J..l.I per well) at a dilution of 1:100 in 5% (w/v) skimmed milk in 
washing buffer solution and incubated for 1 h at 37°C. After washing, protein G-
peroxidase conjugate (Zymed, CA, U.S.A.) was added at a dilution of 1 :5000 in 5% 
(w/v) skimmed milk solution in washing buffer (100 J..l.I) and incubated at 37°C for 1 h. 
The plates were washed and the substrate [Q-phenylenediamine (10 mg) and urea-
hydrogen peroxide (8 mg) in 10 ml sodium citrate buffer 0.1 M, pH 4.5] added (50 
JlVwell) and incubated for 5 min at room temperature in the dark. The reaction was 
stopped by adding 100 J..l.I of 0.5 M sulphuric acid per well. The absorbance of each 
well was read at two wavelengths (492 and 690 nm) using an automatic ELISA plate 
reader (Titertek Multiskan microplate reader, Flow Laboratories, McLean, Va.). A 
commercially available Maedi-Visna virus ELISA kit (Institut Pourquier, Montpellier, 
France) consisting of the p25 antigen only, was used as a reference assay. The ELISA 
procedure and cut-off value determination was performed according to the 
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manufacturer's instructions. All sera were tested in duplicate and mean absorbancies 
were determined for each specimen. 
2.2.11 Selection of sera 
Since no gold standard test for MVV infection exists, flock history and previous 
serological evidence had to be considered as criteria for catagorizing the sheep sera as 
MVV positive or negative. A group of 92 sheep sera was selected as follows: 46 serum 
samples were collected from animals originating from a flock with a history of being 
seropositive to MVV, with macroscopic and histological lesions for MVV infection 
present in some animals at slaughter. These 46 animals tested seropositive on a repeat 
MVV p25 ELISA performed 18 months previously. Another 46 sera were collected 
from sheep originating from flocks with no history of MVV and testing seronegative. 
These animals tested seronegative on more than one occasion during the previous 18 
months. All sheep were between 3-4 years of age. 
2.2.12 Evaluation of ELISA results 
The user-defined template two-graph receiver operating characteristic (TG-ROC) was 
used as a Microsoft-EXCELTM (version 5.0) spreadsheet which selects cut-off values 
in quantitative diagnostic tests (Greiner and Bohning, 1994). The underlying principle 
of this analysis uses a modification of the classical receiver operating characteristic 
(ROC) analysis (reviewed by Zweig and Campbell, 1993). For the construction of the 
TG-ROC plots, the variable range [O.D.min, O.D.maxl as observed for the two reference 
populations is divided arithmetically into 250 intervals with the resulting limits termed 
"thresholds" (dj), Sej and SPj obtained with each threshold value are calculated as the 
proportion of positive results in the positive and negative results in the negative 
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reference population, respectively. The resulting matrix of dj and the corresponding 
percentages Sej and Spj (j = 1. ..... 250) are displayed as a multiple x-y plot, representing 
the two observed parameters over the specified range of O.D. values. These graphs are 
equivalent to the empirical cumulative frequency distribution of the negative (CFDneJ 
and the inverse positive (I-CFDpos) sample. The cut-off (do) that realises equal test 
parameters Sej = Spj = 90 (theta-zero) can be read from the intersection point of the 
two graphs (point of equivalence) with the co-ordinates (do; 90). The intersection of 
the two graphs with the appropriate accuracy level (95 or 90%, respectively) indicates 
two alternative cut-off values, which are the "lower" and "upper limits" of the 
intermediate range (IR). Considering only results outside IR (for 9 < accuracy level), 
the test's Se and Sp would be 95 or 90%, respectively. The valid range proportion 
(VRP) can be established using IR and the measurement range (MR.), the latter being 
defined as the maximal minus the minimal observed test value (VRP = (MR - IR)/MR). 
TG-ROC provides both parametric and non-parametric methods for the estimation of 
measures described above. For the parametric approach the distribution of both 
reference populations should not deviate substantially from normal whereas in the non-
parametric case the analysis does not require any assumptions concerning distribution 
types. 
Using absorbancy data of negative and positive reference samples obtained with the 
GST-TM-p25 ELISA, the software plots the test sensitivity and specificity against the 
cut-off value as the independent variable. From the TG-ROC plots, cut-off values can 
be read for any combination of sensitivity and specificity (Greiner et al., 1995). All 
measures established by TG-ROC are indicated with their appropriate 95% confidence 
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intervals. TG-ROC is public domain software and was obtained from Dr. M. Greiner, 
Free University of Berlin, FRG. 
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2.3 RESULTS 
2.3.1 peR amplification of TM and p25 coding DNA 
A clone of SA-OMVV (obtained from R Vigne, Marseilles, France), was used as 




Figure 2.1 Agarose gel-electrophoretic analysis of purified TM and p25 amplicons. 
Lane1: 273-bp TM amplicon; Lane 2: 748-bp p25 amplicon. 
2.3.2 Sequence analysis of pGEX-MVVrrM-p25 
The recombinant plasmid pGEX-MVV/TM-p25 (Figure 2.2) containing the cloned 
MVV fragments coding for selected regions of the TM and p25 proteins of MVV was 
sequenced as described in Section 2.2.6. 
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Figure 2.2 Diagrammatic representation of GST -TM-p25 expression vector. 
Alignment of pGEX-MVVITM-p25 sequenced and translated co dons, compared with 
SA-OMVV (Querat et al., 1990) sequencing data of corresponding genomic region, is 
shown in Appendix 2. 
2.3.3 Expression, purification and analysis of recombinant proteins 
The plasmid constructs pGEX-MVV/TM, pGEX-MVV/p25 and pGEX-MVVITM-
p25 expressed fusion proteins with molecular weights of 36, 56 and 62 kDa, 
respectively (Figure 2.3). The molecular weights of native GST is 26 kDa (Smith et 
al., 1988), implying that the molecular weight of the cloned MVV TM, p25 and TM-
p25 protein fragments are about 10, 30 and 36 kDa, respectively. The yield of purified 
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Figure 2.3 SDS-PAGE of purified recombinant proteins. Lane 1: GST; 
Lane 2: GST-TM; Lane 3: GST-p25; Lane 4: GST-TM-p25. 
On Western blot analysis, positive MVV sera reacted with all three fusion proteins, but 
not with native GST (Figure 2.4). Negative control sera reacted with neither the fusion 
proteins nor the GST (results not shown). 
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Figure 2.4 Western blot analysis using recombinant proteins as antigens. Lane 1: GST-
TM-p25~ Lane 2: GST-p25~ Lane 3: GST-TM~ Lane 4: GST. 
2.3.4 ELISA evaluation 
2.3.4.1 Two-graph-ROC analysis (TG-ROC) 




Statistical summary of the results of the GST-TM-p25 specific antibody ELISA 
against a positive and negative reference population 
Measure B Negative Positive 
···S~ple·si~e······ ··························46········ ············ ·····46··· ····· ·· 
Mean 0.043 0.792 
Median 0.038 0.779 
Standard deviation 0.024 0.383 
Minimum 0.003 0.117 
Maximum 0.112 1.751 
BTest variables are expressed as OD492 values 
The cut-off (do) as determined by TG-ROC is 0.115 (Table 2.3). This cut-off yields 
equal sensitivity (Se) and specificity (Sp) as test parameters (80 = 0.995) and was 
calculated using the non-parametric programme option. This option was chosen, 
because TG-ROC indicated a deviation from a normal distribution of the test results. 
Table 2.3 
Results of the TG-ROC analysis of the GST-TM-p25 specific ELISA 











a The test variables are expressed as OD492 
values, 95% confidence intervals of point 
estimates are given in brackets. 
b Equality in test parameters (Se=Sp=Bo) 
can be realized when the cut-off do is 
selected. 
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Figure 2.5 TG-ROe analysis of a MVV GST-TM-p2S specific antibody ELISA. The 
intersection point of the two graphs indicates the cut-off point do at which equivalent 
Se=Sp=9o can be achieved. 
The intersection of the two graphs with the appropriate accuracy level (95 or 90%, 
respectively) indicates two alternative cut-off values, which are the "lower" and "upper 
limits" of the intermediate range (IR). The valid range proportion (VRP) can be 
established using IR and the measurement range (MR), the latter being defined as the 
maximal minus the minimal observed test value (VRP = (MR - IR) / MR.). 
2.3.4.2Jt()(: plot 
In Figure 2.6 a ROe plot of the GST -TM-p25 fusion protein ELISA was constructed 
using the software described above for the TG-ROe plot. In this graph the value of 
1 - Spj is plotted on the x-axis (independent variable) and the value of S~ is plotted 
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Figure 2.6 ROe plot of the GST-TM and GST-TM-p25 specific ELISA. 
Thus the ROe graph is a plot of all the sensitivity/specificity pairs resulting from 
continuously varying the decision threshold over the entire range of results observed. 
In each case, the ROe plot depicts the overlap between the two distributions by 
plotting the sensitivity (or true positive fraction) versus 1- specificity (or false-positive 
fraction) for the complete range of decision thresholds. As shown in Figure 2.6 the 
GST -TM-p25 ELISA has a ROe plot that passes through the upper left corner, where 
the true-positive fraction is 1.0 or 100% (perfect sensitivity), and the false-positive 
fraction is 0 (perfect specificity). 
2.3.4.3 Comparison of the GST-TM-p25 ELISA with a commercial p25 ELISA 
Each of the GST-TM and GST-TM-p25 ELISA results for the 46 negative and 
positive reference sera was evaluated using the TG-ROe calculated cut-off value. 
These results were then statistically compared (Table 2.4) with the results obtained 




Comparison of recombinant GST -TM-p25 and GST -TM with a commercial MVV 
p25 test kit. Characteristics are based on testing 46 negative and positive reference 
sera 
Immunoassay TPIPR Sensitivity TNINR Specificity 
% % ........................................................................................................................................................... 
Commercial 40/46 87 46/46 100 
p25 
GST-TM 46/46 100 45/46 98 
GST-TM-e25 46/46 100 46/46 100 
a TP, number of test-positive samples; PR, number of positive-reference 
sera tested; TN, number of test negative samples; NR, number of negative 
reference sera tested. 
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2.4 DISCUSSION 
Several studies have shown that the agar gel immunodiffusion (AGID) test by itself is 
not sufficient for MVV diagnosis because it lacks sensitivity (Houwers et al., 1982~ 
Vitu et aI., 1982~ Simard and · Briscoe, 1990). Second-generation recombinant protein 
assays solved many of the problems associated with the previous generation assays 
which used virallysates. 
The core (P25) and transmembrane (gp40) proteins encoded for by the gag and env 
genes were selected as diagnostic proteins because collective data suggested that MVV 
infected sheep produce a strong immune response against the core protein early in 
infection which is followed by a strong transmembrane immune response in the later 
stages of disease (Kajikawa et al., 1990). This is analogous to the situation in human 
beings infected with HIV-l (Atlain et aI., 1986). Thus, antibodies against gag and env 
protein products increase and decrease inversely through progression of the disease. 
Therefore, any individual serum may react with only one antigen during the course of 
MVV infection, but it is believed to be unlikely that serum from an infected sheep will 
not react with either of them. The conclusion can therefore be made that the ideal 
serologic assay for MVV should contain at least these two antigens to diagnose 
infected animals at all stages of disease. This was achieved by cloning both the p25 and 
TM genes in frame in the same expression cassette (Figure 2.2). Sequence analysis and 
expression of these two antigens as a combined fusion protein with glutathione S-
transferase (GST) as fusion partner (Figure 2.3) confirmed that the correct genes had 
been cloned and that the codons were in frame. 
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The GST expression vector allows for inducible, high-level expression of proteins and 
has been used to produce recombinant caprine, equine, human, ovine and simian 
lentiviral fusion proteins (Zanoni et al., 1991; Beatty et al., 1992; Kwang and Cutlip, 
1992a,b; Mills et al., 1992; Thomas et al., 1992; Rimstad et al., 1994). However, 
certain foreign proteins often do not express well. Typically, problems encountered 
with protein expression in prokaryotic systems can be traced to over-expression of the 
foreign protein causing protein aggregation, toxicity of expressed protein or 
intracellular proteolytic degradation. Additionally, elevated temperatures lead to 
enhanced expression of the heat-shock proteins such as DnaK and GrpE which 
participate in the degradation of foreign and abnormal proteins in E. coli (Echo Is, 
1990; Sherman and Goldberg, 1992). It is also our experience that such co-purified 
proteins often cause unacceptable ELISA background signals, making them unsuitable 
for the development of sensitive assays. Although overexpression of a protein at an 
elevated temperature leads to a higher yield, this advantage is often counteracted by 
aggregation and/or enhanced proteolysis of the protein. Most of the problems 
mentioned above could be circumvented by inducing the E. coli cell culture with IPTG 
at 20°C instead of 37°C (Ghosh et al., 1995) and using an improved purification 
protocol as previously described (Grieco et al., 1992). 
The establishment of a reliable cut-off value is essential for a serologic test of 
diagnostic significance. This requires the selection of a cut-off value that will 
differentiate between sUbpopulations of infected and non-infected individuals with a 
stated diagnostic accuracy (Greiner and B6hning, 1994). Cut-off values in enzyme-
linked immunosorbent assays (ELISA) have often been established as the mean plus 
two standard deviations of values from a non-infected population. Barajas-Rojas and 
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colleagues (1993) pointed out that this approach leads automatically to a specificity of 
97.5% provided that the test variables are normally distributed. However, deviations 
from normality are often seen in serodiagnostic data which should be taken into 
account when selecting legitimate cut-off values (Vizard et al., 1990). Furthermore, 
the sensitivity (Se) and specificity (Sp) of an assay always inversely influence each 
other so that only the entire spectrum of sensitivity/specificity pairs provides a 
complete picture of test accuracy (Zweig and Campbell, 1993). 
These factors are all taken into consideration by using the two-graph recelver 
operating characteristic (TG-ROG) plot to establish a cut-off value. In TG-ROC, Se 
and Sp are plotted separately as dependent variables against the assumed cut-off value 
as the independent variable ( Figure 2.3). The estimated cut-off do then reflects equal 
Se and Sp with the resulting test parameter ( Se = Sp = e) (Table 2.3). 
TG-ROC can also be used to determine "intermediate" test results by establishing two 
alternate cut-off values. The intermediate range (IR) for an ideal test should be equal 
to zero because the upper limit ofIR is less than the lower limit. In such a case a single 
cut-off value can be selected. The valid range proportion (VRP) would then be 1.0 and 
both Se and Sp would be greater than or equal to 95%. This is the case for the 
described GST -TM-p25 ELISA assay which shows a zero IR value and a resultant 
VRP value of 1.0 (Table 2.3). In Figure 2.4 a plot of all the sensitivity/specificity pairs 
resulting from continuously varying the decision threshold over the entire range of 
results is shown. Sensitivity, or the true-positive fraction [defined as ( number of true-
positive test results) I (number of true-positive + number of false-negative test results)] 
is plotted on the y-axis and the false-positive fraction, or 1 - specificity [defined as 
(number of false-positive results) / (number of true-negative + number of false-positive 
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results)] is plotted on the x-axts. The GST-TM-p25 ELISA showed perfect 
discrimination (no overlap in the two distributions) and has an ROe plot that passes 
through the upper left corner, where the true-positive fraction is 1.0 or 100% (perfect 
sensitivity) and the false-positive fraction is 0 (perfect specificity). Table 2.4 further 
illustrates these results and emphasises the increased sensitivity obtained with the 
inclusion of the TM antigen compared to a commercial MVV p25 ELISA kit. 
All previously described recombinant MVV ELISA assays utilised either the p25 or 
TM proteins alone (Reyburn et al., 1992; Kwang et al., 1993) or combined (Keen et 
al., 1995), but as individual proteins. In this chapter the cloning and expression of both 
proteins as a single fusion protein is described and demonstrated the need for both 
proteins to ensure a sensitive assay. The GST fusion protein was not cleaved from the 
antigens used in this study. All sera were tested against GST alone but none had 
antibodies to the GST. This was slightly unexpected as there have been unpublished 
reports that a low percentage of sheep have anti-GST antibodies. The next phase of 
this study will include a much larger population of animals. The anti-GST problem will 
be further investigated and the sensitivity and specificity of this assay will be compared 
with other confirmatory criteria such as molecular diagnosis and pathology. 
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CHAPTER 3 
INVESTIGATING THE USE OF THE METHYLOTROPIC 
YEAST, PICHIA PASTORIS, FOR THE EXPRESSION OF A 
MVV TM-POL YPEPTIDE 
3.1 INTRODUCTION 
In mv, the transmembrane (TM) glycoprotein portion of the envelope viral protein 
has been identified as the antigen most consistently recognised by antibodies 
(Schupbach et al., 1984~ Barin et al., 1985). Recombinant polypeptides representing 
regions of the TM and synthetic oligopeptides corresponding to highly antigenic 
segments of the mv TM have been used for serodiagnosis of the human AIDS viral 
infections (Wang et aI., 1986~ Cabradilla et al., 1986~ Gnann et al., 1987). Results 
presented in Chapter 2 (Table 2.4) seem to indicate that the same applies to MVV as 
the GST -TM fusion protein, expressed in E. coli, has comparable sensitivity to the 
GST -TM-p25 fusion protein, but lacks specificity. This is probably due to the fact that 
the MVV TM protein is known to be hydrophobic (Querat et al., 1990), and difficult to 
purify using conventional induction and purification protocols (Kwang et al., 1993). 
Despite the fact that a truncated version of the TM protein was expressed (Figure 2.3), 
special induction and purification procedures had to be adopted (Section 2.2.7) in 
order to purify the fusion protein, free of contaminating E. coli proteins. The 
successful development of sensitive diagnostic methods for HIV based on TM-
polypeptides stimulated the search for a reliable, sensitive and continuous source of 
pure MVV TM-polypeptide to be used in an ELISA. 
The yeast Pichia pastoris, representing one of four different genera of methylotrophic 
yeasts, which also include Candida, Hansenula, and Torulopsis, was shown to be 
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suitable for the high-level expression of vanous heterologous proteins, either 
intracellularly localised (Cregg and Madden, 1988~ Clare et al., 1991) or secreted into 
the culture supematant (Tschopp et al., 1987b~ Digan et al., 1989). P. pastoris 
combines the features of a eukaryotic secretion machinery with the fast growth and 
simple growth media requirements of bacteria (Cregg et al., 1993). Additionally, the 
induction can be efficiently regulated by the supplementation of methanol as the carbon 
source and high levels of heterologous proteins expression require only small scale 
production in shake flasks. These features made P. pastoris an attractive host for the 
expression of the hydrophobic transmembrane protein of MW. 
P. pastoris is capable of metabolising methanol as a sole carbon source (Veenhuis et 
al., 1983). From an expression system perspective, the most interesting aspect of this 
metabolic pathway was alcohol oxidase (AOX), the first enzyme in the methanol-
utilisation pathway (Ellis et aI., 1985~ Koutz et al., 1989) (see Figure 3.1). 
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Figure 3.1 Overview of methanol metabolism in yeast. 
AOX, alcohol oxidase; DHAS, dihydroxyacetone synthase; XusP, xylulose 5-
phosphate; GAP, glyceraldehyde 3-phosphate. 
AOX is undetectable in cells cultured on carbon sources such as glu~ose, glycerol or 
ethanol, but constitutes up to 30% of total soluble protein in methanol-grown cells 
(Couderc and Baratti, 1980). It was anticipated that AOX synthesis would be 
regulated at the transcriptional level and that the promoter for this gene would be most 
useful for controlling the expression of foreign genes. Under control of an AOX 
promoter, foreign genes could be maintained in an "expression-oft" mode on a non~ 
methanolic carbon source to minimise selection for nonexpressing mutant strains 
during cell growth, then efficiently switched on by shifting to methanol. Another 
advantage of expressing secreted proteins is that P. pastoris secretes very low levels of 
native proteins. That, combined with the very low amount of protein in the growth 
medium, means that the secreted heterologous protein comprises the vast majority of 
the total protein in the medium and this simplifies the purification of the protein. 
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The P. pastoris expression system is based on a histidinol dehydrogenase-defective 
mutant host strain, G1l5. The expression plasmid which contains the complete P. 
pastoris HIS4 gene can complement the mutant P. pastoris host defect and therefore 
be used as a selectable marker (Cregg et aI., 1985). The expression vector is also 
designed to be linearized with the restriction enzyme, BgI II, such that His + 
recombinants can be generated by integration at the AOX1 locus. This integration can 
result in the complete removal of the AOX1 coding region (Le. gene replacement) that 
in turn results in a recombinant phenotype ofHis+ Mut- (MuC refers to the methanol 
utilisation minus phenotype caused by the loss of alcohol oxidase activity encoded by 
the AOX1 gene that results in a no growth or slow growth phenotype on methanol 
media). The events as described above are illustrated in Figure 3.2. 
Plasmid pPIC9 is an Escherichia coli- P. pastoris shuttle vector, With sequences 
required for selection in each host (Figure 3.2). The left half of the plasmid is a portion 
of pBR322, from Cia I site through the Pvu II site (modified to a BgIII site). This 
segment of pBR322 contains the ampicillin resistance gene (AmP) and the E. coli 
origin of replication (ori). The EcoR I site in this segment has been eliminated. There is 
no fl-bacteriophage origin of replication. The DNA elements comprising the rest of the 
plasmid are derived from the genome of P. pastoris with the exception of the 
Saccharomyces cerevisiae a-factor secretion signal and sequence (pre-pro sequence), 
the multiple cloning site and short regions of pBR322 used to link the yeast elements. 
The P. pastoris elements in the plasmid are as follows: 
1) 5' AOX1, approximately 1000 bp segment of the alcohol oxidase promoter fused to 
the Saccharomyces cerevisiae a-factor secretion signal sequence with Xho I, 
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Hind Ill, SnaB I, EcoR I, AvrIl and Not I cloning sites. 
2) 3' AOXl, approximately 256 bp segment of the alcohol oxidase terminating 
sequence. 
3) P. pastoris histidinol dehydrogenase gene, HIS4, contained on a 2.4 Kb fragment to 
complement the defective His4 gene in host GS 115. 
4) Region of 3' AOXl DNA approximately 650 bp in size, which together with the 5' 
AOXl region is necessary for site-specific integration by homologous recombination. 
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Figure 3.2 Outline of the cloning, transfonnation, recombination and selection of 
P. pastoris clones expressing a specific gene of interest. 
Expression of the foreign DNA is achieved by integration into the P. pastoris genome 
which ensures stable recombinant cell lines (Schiestl and Gietz, 1989). The site of 
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integration however, also detennines the selection of resultant transformants. 
Transformation of GS 115 with Bgl II-linearized pPIC9 constructs resulted in 
recombination with the AOXI locus (see Figure 3.2). Displacement of the alcohol 
oxidase (AOXI) structural gene occurs at a frequency of 5-35% of the His+ 
transformants. Because these transformants are not producing alcohol oxidase, they 
can not efficiently metabolise methanol (see Figure 3.1) as a carbon source, and 
therefore grow poorly on media containing methanol as sole carbon source. This slow 
growth on methanol phenotype can be used to distinguish His + transformants in which 
the AOXI gene has been disrupted (His + Muf) from His + transformants with an intact 
AOXI gene (His + Mut). Protein producing clones can easily be scaled up from shake 
flask to fermentor (Cregg and Madden, 1988). This expression system has also been 
shown to successfully . express a wide variety of proteins ranging in size from 6 KDa to 
135 KDa (Tschopp et al., 1987a; Vedvick et aI., 1991). To conclude, P. pastoris has 
proven to be a powerful tool for the production of foreign proteins of both academic 
and commercial interest (Wegner, 1990). Advantages of the system include: (I) the 
AOXI promoter which has transcription characteristics useful for regulating 
heterologous protein expression; (2) well-developed methods for classical- and 
molecular-genetic manipulation of the organism; and (3) technology for the growth of 
expression strains in large high-density fermentor cultures. These advantages prompted 
investigating the use of the P. pastoris expression system for the expression of the 
MVV TM-polyprotein as discussed above. 
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3.2 MATERIALS AND METHODS 
3.2.1 Polymerase Chain Reaction (PCR) 
A coding region from the TM gene ofMVV was amplified as a 117-bp DNA fragment 
by PCR essentially as described in Section 2.2.1. The 5' primer was designed to amplify 
the TM region with an EcoRl restriction site and the 3' primer with a Not I 
restriction site (Table 3.1). 
Table 3.1 
The nucleotide sequences and genomic locations of PCR primer pairs used to PCR 
amplify the MVV TM coding region to be expressed in P. pastoris. 
Primer Sequence (5'-3') Gene and location* 
........................................................................................................................................................................................................................................ 
TM-His 5' primer TCC AGG GAA TTC CAT CAT CAT CAT env (8084-8101) 
CAT CAT GAA GCT ATA GTC GAT AGA 
TM 3' primer TCC CGG GCG GCC GCA TAT CTT GTC env (8201-8183) 
CAA TTT AC 
* See Querat et aI., 1990. 
The TM-His 5' primer contains six consecutive histidine co dons designed to be in 
frame with the pPIC9 P. pastoris expression vector (see Section 3.2.2). The resultant 
PCR product (Figure 3.3) was purified (Spin kit, Qiagen, Chatsworth, CA, D.S.A.) 
and subsequently digested with EcoRl and NotI restriction enzymes. 
3.2.2 Construction of yeast expression vector for MVV TM-polypeptide 
The pPIC9 vector DNA was linearized by digesting with EcoRl and Not I restriction 
enzymes as described in Section 2.2.2. Since two restriction enzymes were used no 
dephosphorylation of the 5' phosphate groups, to prevent recircularization, was 
necessary. Ligation of the 117-bp TM-polypeptide coding DNA insert to the linearized 
pPIC9 vector was done as described in Section 2.2.3. Subsequent transformation of 
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ligated pPIC9 DNA using competent E. coli JMI09 cells was perfonned as described 
in Section 2.2.4. Small-scale isolation of pPIC9 DNA to verify the presence of the 
correct size insert was done as described in Section 2.2.S using EcoRI and Not I 
restriction enzymes. Sequencing of the cloned fragment to confinn that it was in the 
correct reading frame was perfonned as described in Section 2.2.6 using the 
sequencing primers included in the Pichia expression kit (Invitrogen). The nucleotide 
sequences of the above mentioned sequencing primers are given in Appendix 1. 
3.2.3 Growth and storage of yeast strains 
The growth temperature for P. pastoris is 30°C for liquid cultures (with shaking), 
plates and slants. Since the P. pastoris GS lIS strain is defective in its histidinol 
dehydrogenase activity coded for by the HIS4 gene, GS lIS will only grow on complex 
media such as ypn or on minimal media supplemented with histidine, such as MMH, 
MDH or MGYH. Until transfonned, GS lIS will not grow on minimal media such as 
RD, MM, MD or MGY (see Appendix 1 for media descriptions). Yeast strains can be 
stored at -70°C in IS% glycerol (viable for >S years) or at 4°C on YPD agar slants 
(viable for 1 to 2 years). The GSIIS His+ transfonnants for storage are initially 
cultured in selective medium (MGY or MD) harvested and suspended in ypn 
containing IS% glycerol, frozen and stored at -70°C. 
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3.2.4 Preparation of transforming DNA 
Large-scale preparation of recombinant pPIC9 vector DNA was done using a maxiprep 
plasmid isolation kit from Qiagen (Chatsworth, CA, U.S.A). The plasmid DNA was 
digested with Bg/ II restriction enzyme (pharmacia Biotech. U.S.A), to obtain His+ 
Muf transformants (see Figure 3.2). After digestion, two plasmid fragments were 
generated. This was confirmed by agarose gel electrophoretic analysis (Section 2.2.1). 
A non-recombinant pPIC9 plasmid digestion was also included as a negative protein 
expression control. 
3.2.5 Preparation of spheroplasts 
The host strain GS 115 was streaked onto a YPD plate and incubated at 30°C for 2 
days. A 10 ml solution of YPD was inoculated with a single colony and grown 
overnight at 30°C with vigorous shaking. This culture was used as inoculum in the 
subsequent steps and could be stored at 4°C for several days. A 200 ml YPD solution 
was inoculated with 5 III of inoculum solution and incubated overnight with vigorous 
shaking at 30°C. Once an O.D.6oo of 0.2 ~ 0.3 was reached, cells were harvested by 
centrifugation (1500 x g, 10 min, RT), washed with freshly prepared SED (1 M 
sorbitol, 25 mM EDTA, 50 mM DTT, pH 8.0) and with 1 M sorbitol, with 
intermediate centrifugation as before. The cells were resuspended in 20 ml SCE (1 M 
sorbitol, 1 mM EDTA and 10 mM sodium citrate buffer, pH 5.8) and divided into two 
tubes containing 10 ml each. Zymolyase (3 mglml in water) which is provided as a 
slurry was mixed thoroughly before 8 J.lI (24 Ilg) was added to one tube of cells, mixed 
and incubated at 30°C. Monitoring of the percentage spheroplasting was done by 
adding 200 J.lI of the Zymolyase containing cell suspension to 800 III of 5% SDS at 
71 
time t=O, 2, 4, 5, 6, 7, 8, 9, 10, 15, 20 and 30 min after Zymolyase addition and 
measuring the O.D.800. Determination of the percent of spheroplasting for each time 
point was calculated using the equation: 
% Spheroplasting = 100 - [(OD800 at time t/OD8oo at time 0) x 100] 
The time needed to obtain 70% spheroplasting was determined and the spheroplasting 
step repeated on the second tube of cells. The spheroplasts were harvested by 
centrifugation (750 x g, 10 min, RT) and washed with 10 m11 M sorbitol and 10 ml 
CaS (1 M sorbitol, 10 mM Tris-HCI, pH 7.5, 10 mM CaCh) with intermediate 
centrifugation (750 x g, 10 min, RT). The spheroplasts were gently resuspended in 0.6 
ml of CaS and immediately used for transformation. 
3.2.6 Transformation 
For each transformation performed, a 100 J.lI solution of spheroplasts from Section 
3.2.5, was dispensed into a sterile 6 ml snap-top microcentrifuge tube. The linearized 
recombinantand non-recombinant pPIC9 vector DNA (2 - 5 J.lg), prepared as 
described in Section 3.2.4, was added to each of the spheroplast containing tubes and 
incubated at room temperature for 10 min. Bg/ II digested non-recombinant pPIC9 
vector DNA was used to obtain negative expression control clones. No DNA was 
added in the negative control transformation tube. A freshly prepared PEG/CaT [1: 1 
mixture of 40% PEG and CaT (20 mM Tris, pH 7.5, 20 mM CaCh)] solution (1 ml) 
was added, gently mixed and incubated at room temperature for 10 min. Each 
transformation tube was subsequently centrifuged (750 x g, 10 min, RT) the PEG/CaT 
solution aspirated and the pellet of transformed cells was resuspended in 150 J.lI SOS 
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medium (1 M sorbitol, 0.3X YPD, 10 mM CaCh) and incubated at room temperature 
for 20 min. Before plating, 1 M sorbitol (850 ~l), was added. 
3.2.7 Plating for transform ants 
A 200 ~l aliquot offreshly transformed spheroplasts was added to 10 ml of molten RD 
which was held at 45°C, and poured onto corresponding RDB base . plates (see 
Appendix 1 for composition of media). The top agar was allowed to harden and the 
plates inverted and incubated at 30°C. Transformants appeared within 5-7 days. The 
negative controls should not form colonies. 
3.2.8 Screening for AOXl-disrupted transformants 
Using a sterile toothpick, His+ transformed colonies were picked and used to inoculate 
a test tube containing 2 ml YPD for each colony. After an overnight shaking incubation 
at 30°C, separate test tubes containing 2 ml BMGY and 2 ml BMMY each, were 
inoculated with 1 0 ~l of the individual colonies, respectively. The cultures were 
allowed to grow for 24 h shaking at 30°C. Visual comparison of any growth difference 
observed for each colony could be established after allowing the cells t9 settle 
overnight at 4°C. The GS1l51His+ Muf albumin secreting and GS1l5 host strain, 
supplied with the P. pastoris Expression Kit (Invitrogen), were used as positive and 
negative AOXl disrupted controls, respectively. 
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3.2.9 Expression of recombinant MVV TM-polypeptide 
Fifty two colonies displaying poor growth on BMMY medium (His+ Mut- phenotype) 
were identified as described in Section 3.2.8. Selective MD agar plates were used to 
maintain the individual clones before each colony was inoculated into 10 m1 BMGY 
medium and grown for two days at 30°C with vigorous shaking until the cells reached 
an 0.D.600 > 10.0. The cells were harvested by centrifugation 4000 x g, 10 min, RT). 
The supematants were discarded and the individual pellets resuspended in 2 m1 BMMY 
medium and grown as before for another two days. The MVV TM-polypeptide 
containing supematants were obtained by centrifugation as described and used in 
subsequent steps. 
3.2.10 ELISA evaluation of expression supernatants 
The 52 putative MVV TM-polypeptide containing supematants were tested for 
reactivity towards MVV positive sera using the ELISA technique. To each 
supematant, PMSF and EDTA were added to give the final concentrations of 1.0 mM 
and 5 mM, respectively, diluted 1:1 with 100 mM sodium bicarbonate pH 9.6, and 
dispensed at 100 J..lI per microtitre well (Greiner, Germany). The solution was dried by 
evaporation overnight at 37°C. The plates were washed three times with washing 
buffer [50 mM Tris-HCl, 150 mM NaCI, pH 8.0 containing 0.05% (v/v) Tween 20]. 
The ELISA procedure was performed as described in Section 2.2.10 and the selection 
of positive and negative MVV serum based on the criteria described in Section 2.2.11. 
Control P. pastoris expression supematants obtained as described in Sections 3.2.4, 
3.2.6 and 3.2.8 were used as negative control supematants. 
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3.2.11 peR analysis ofMVV TM-polypeptide expressing clones 
Total DNA was isolated from clones identified to express the MVV TM-polypeptide 
as determined above by ELISA. The individual clones were grown to an O.D.6oo > 5.0 
in 10 ml MD medium at 30°C. The cells were centrifuged at 1500 x g, washed with 10 
ml sterile water before being resuspended in 2 ml SCE buffer, pH 7.5, containing DTT 
(1 M sorbitol, 10 mM sodium citrate, 10 mM EDTA, 10 mM DTT). Zymolyase (0.3 
mg) was added to each cell suspension and incubated at 37°C to achieve < 80% 
spheroplasting (monitored as described in Section 3.2.5.) Two ml of 1% SDS was 
added, gently mixed and set on ice for 5 min, before 1.5 ml of 5 M potassium acetate, 
pH 8.9, was added. The lysed cell suspensions were centrifuged at 10 000 x g for 10 
min and the supematants retained. Two volumes of ethanol were added to each of the 
supematants and incubated at room temperature for 15 min. The solutions were 
subsequently centrifuged at 10 000 x g for 10 min and the resultant DNA pellets gently 
resuspended in 0.7 ml TE buffer (10 mM Tris-HCI, pH 7.4, 1 mM EDTA, pH 8.0) and 
transferred to a micro centrifuge tube. Contaminating protein was extracted with an 
equal volume of phenol:chloroform:isoamylalcohol (25:24:1) followed by an equal 
volume of chloroform. The purified genomic DNA was precipitated by adding 112 a 
volume of 7.5 M ammonium acetate, pH 7.5, and 2 volumes of ethanol to each tube. 
The tubes were incubated at -20°C overnight before being centrifuged at 10 000 x g 
for 20 min. The DNA pellets were each washed once with 1 ml 70% ethanol, dried and 
then resuspended in 50 J.lI ofTE buffer, pH 7.4. PCR amplification of the 117-bp MVV 
TM-polypeptide was carried out with the TM-His 5' and TM 3' primers (Table 3.1), 
using the isolated genomic DNA as template. The PCR was essentially as described in 
Section 2.2.1, except that the samples were amplified for 30 cycles, each cycle 
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consisted ofa denaturation step at 94°C for 1 min, followed by annealing at 55°C for 1 
min and extension at 72°C for 30 seconds. DNA isolated from the host strain, GS115 
and a His + Muf clone obtained by transforming with non-recombinant linearized pPIC9 
vector (see Section 3.2.4) were used as negative control template DNA. Visualisation 
of the amplicons was as described in Section 2.2.1. 
3.2.12 Large-scale expression and purification of the secreted MVV TM-
polypeptide 
Expression of the MVV TM-polypeptide was performed in shake flasks in 100 ml of 
BMGY medium at 30°C to an O.D.6oo > 15. The cells were subsequently harvested and 
resuspended in 50 ml ofBMMY (methanol induction), containing 2 mM PefabloC® SC 
(Boehringer Mannheim), and incubated at 30°C for 96 h to induce expression. 
Expression supernatant aliquots were taken every 24 h and tested by ELISA (see 
Section 3.2.10) to determine the optimum time of TM-polypeptide expression as 
reflected by ELISA reactivity. Separation of protein by SDS-PAGE and subsequent 
transfer to a nitrocellulose membrane for Western-blot analysis was performed as 
described in Sections 2.2.8 and 2.2.9. The histidine-tagged MVV TM-polypeptide was 
purified using immobilised metal affinity chromatography (IMAC) (porath and Olin, 
1983). The principle behind IMAC lies in the fact that many transition metal ions, i.e. 
nickel, can co-ordinate to histidine via electron donor groups (Sulkowski, 1985). In 
order to utilise this interaction for chromatographic purposes, the metal ion must be 
immobilised onto an insoluble chromatographic matrix. It is coupled to a matrix such 
as Sepharose 6B, via a long hydrophilic spacer arm. The spacer arm ensures that the 
chelating metal is fully accessible to all available binding sites on a protein. The basic 
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methodology of IMAC consist of three steps: (1) charging the gel, (2) binding the 
proteins, and (3) eluting the proteins. A Ni-NT A (nickel-nitrilotriacetic acid) (Qiagen) 
resin for proteins with an affinity tag of six consecutive histidine residues (6x His tag) 
was used. It is supplied pre-swollen and charged with Ni2+ as an aqueous suspension 
(50%). The Ni-NTA resin contains 8-12 J..lmol Ne+/ml gel and has a binding capacity of 
approximately 5-10 mg protein per ml resin, however, the capacity of the resin may 
vary to some extent with the size and shape of the recombinant protein. After optimum 
time of induction was reached the TM-polypeptide containing supematant was 
adjusted to pH 8.0 with 0.1 M NaOH and PMSF and ~-mercaptoethanol were added 
to a final concentration of 1 mM and 10 mM, respectively. No EDT A was added as 
this will inhibit binding of the 6x His tagged TM-polypeptide to the Ni-NTA resin. The 
supematant was passed twice through the Ni-NTA column before washing the resin 
with washing buffer (0.1 M sodium phosphate, 0.01 M Tris-HCI, pH 8,0 containing 10 
mM imidazole) until the A280 of the eflluent was <0.01. The MVV TM-polypeptide 
was eluted with 10 ml washing buffer containing 200 mM imidazole as competitor and 
collected in 1 ml fractions. Expressed protein was precipitated as follows: The sample 
to be concentrated was transferred to an Eppendorf tube and 1110 volume of 5% SDS 
added. The tube was inverted a few times and 1/10 volume 3 M KCI added. After a 
few more inversions the sample was centrifuged (12 000 x g, 5 min, RT). The resultant 
protein pellet was resuspended in 1110 the original volume of 100 mM sodium 
carbonate pH 9.6, ELISA coating buffer. Optimum coating concentration was 
determined by titration of the purified MVV TM-polypeptide and adsorption onto 
ELISA plates (Greiner, Germany) performed as described in Section 3.2.10, at the 
determined optimum dilution. 
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3.2.13 Two-graph receiver operating characteristic (TG-ROC) analysis 
The user-defined template two-graph receiver operating characteristic (TG-ROC) was 
used as a Microsoft-EXCELTM (version 5.0) spreadsheet which selects cut-off values 
in quantitative diagnostic tests (Greiner and Bohning, 1994) as described in Section 
2.2.12. Absorbancy data of negative and positive reference samples, obtained with the 
P. pastoris expressed MVVTM-polypeptide ELl SA, were used to pIoUest sensitivity 
and specificity against the cut-off value as the independent variable. All measures 
established by TG-ROC are indicated with their appropriate 95% confidence intervals. 
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3.3 RESULTS 
3.3.1 peR amplification of TM-polypeptide coding DNA 
A clone of SA-OMVV (obtained from R. Vigne, Marseilles, France), was used as 
template for the amplification of a 117-bp DNA fragment (Figure 3.3). Primer 
sequences are shown in Table 3.1. 
Fi~re 3.3 Agarose (2% w/v) gel-electrophoretic analysis of purified TM-polypeptide 
codmg DNA produced by peR. Lane 1: 117-bp amplicon. 
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3.3.2. Sequence analysis of pPIC9-TM recombinant plasmid 
The recombinant plasmid pPIC9-TM containing the cloned Il7-bp TM-polypeptide 
coding DNA was sequenced as described in 2.2.6. Sequences of the sequencing 
primers are shown in Appendix 1. Alignment of the . pPIC9-TM sequenced and 
translated co dons compared with SA-OMVV (Querat et al., 1990) sequence data of 
the corresponding genomic region are shown in Appendix 3. The Il7-bp TM-
polypeptide coding DNA fragment has been cloned in frame with the P. pastoris 
pPIC9 vector to be expressed as a secreted polypeptide with six consecutive N-
terminal histidine amino acid residues. However, a nine nucleotide deletion occurred, 
which might be due to a PCR artefact, without altering the reading frame of the cloned 
MVV-TMDNA (see Appendix 3). 
3.3.3 PCR analysis of putative positive P. pastoris integrants 
Two clones designated as A2 and B 11 were identified as both AOXl-disrupted 
(Section 3.2.8) as well as TM-polypeptide expressing (Section 3.2.9) transformants as 
identified by ELISA evaluation of expression supernatants (Section 3.2.10). Genomic 
DNA from the above mentioned transformants was analyzed to determine if the gene 
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Figure 3.4 Agarose (2% w/v) gel-electrophoretic analysis of PCR products of 
genomic DNA isolated from clones A2 (lane 1), BII (lane 2), host cell GSII5 (lane 3) 
and pPIC9 plasmid-only transformant negative control transformant (lane 4). 
PCR amplification of the gene of interest was carried out with the TM-His 51 primer 
and TM 31 primer as shown in Table 3.1. Confirmation of integration of the TM-
polypeptide coding gene was established for both transformants A2 and B 11 (Figure 
3.5, lanes 1 and 2, respectively). Genomic DNA isolated from the host cell line GSl15 
and the pPIC9 plasmid-only transformant negative expression control transformant, 
obtained as described in Section 3.2.4, served as negative controls (Figure 3.5, lanes 3 
and 4, respectively). 
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3.3.4 Purification of the secreted TM-polypeptide 
Seventy two h of growth on 0.5% methanol, was found to be the optimum time of 
expression, whereafter the supernatant was collected and the histidine-tagged MVV 
TM-polypeptide purified using immobilised metal chelate affinity chromatography as 
described in Section 3.2.12. 
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Figure 3.5 Purification of the P. pastoris expressed histidine-tagged MVV TM": 
polypeptide by metal chelate affinity chromatography. Pool 1 contains the histidine-
tagged MVV TM-polypeptide. 
Protein yield, determined using the micro-Lowry assay, revealed a concentration of 
40 Jlg TM-polypeptide from 50 ml of culture supernatant. This implied that the 
supernatant had a concentration of less than 1 J..lg/ml TM-polypeptide. 
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3.3.5 SDS-PAGE and Western-blot analysis ofMVV TM-polypeptide 
As a result of the low concentration of the secreted MVV TM-polypeptide, 
visualisation after electrophoretic separation with either Coomassie or silver staining 
(data not shown) of the expected 5 kDa protein was difficult. Furthermore, Western 
blot analysis of the concentrated TM-polypeptide using nitrocellose membranes, 
yielded no positive reaction. ELISA, as described in 3.2.10, remained the only way to 
detect and evaluate the diagnostic value of the P. pastoris expressed MVV TM-
polypeptide. 
3.3.6 Evaluation of the P. pastoris expressed TM-polypeptide ELISA 
3.3.6.1 Two-graph-ROC analysis (TG-ROC) 
Statistical variables of the negative and positive reference samples are summarized in 
Table 3.2. 
Table 3.2 
Statistical summary of the results of the P. pastoris expressed MVV TM-polypeptide 
ELISA against a positive and negative reference population 
Measurea Negative Positive 
Mean 0.210 0.487 
Median 0.168 0.381 
Standard deviation 0.175 0.312 
Minimum · 0.009 0.032 
Maximum 0.898 1.631 
aTest variables are expressed as O.D.492 values 
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The cut-off (do) as determined by TG-ROC is 0.256 (Table 3.3). This cut-off yields 
equal sensitivity (Se) and specificity (Sp) as test parameters (8 = 0.833) and was 
calculated using the non-parametric programme option. This option was chosen, 
because TG-ROC indicated a deviation from a normal distribution of the test results. 
Table 3.3 
Results of the TG-ROC analysis of the P. pastoris expressed MVV TM-polypeptide 
specific ELISA . 
Measurea. b Non-parametric 
80 0.833 
do 0.256 (0.225, 0.276) 
IR 0.493 (0.237, 0.861) 
upper limit 0.566 (0.44, 0.893) 
lower limit 0.073 (0.032, 0.203) 
VRP 0.696 (0.469, 0.854) 
a The test variables are expressed as O.D.492 
values, 95% confidence intervals of point 
estimates are given in brackets. 
b Equality in test parameters (Se=Sp=8o) 
can be realised when the cut-off do is 
selected. In order to meet the accuracy criteria 
(90 or 95%, respectively), two cut-off values are 
selected, to determine the intermediate range 
(IR) and the valid range proportion (VRP). 
The cut-off (do) can be read directly from the TG-ROC graph (Figure 3.6). 
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Figure 3.6 TG-ROC analysis of the P. pastoris expressed MW TM-polypeptide 
specific antibody ELISA. The interSection point of the two graph indicates the cut-off 
point do at which equivalent Se=Sp=9o can be achieved. 
The interSection of the two graph with the appropriate accuracy level (95 or 90%, 
respectively) indicate two alternative cut-off values, which are the "lower" and "upper 
limits" of the intennediate range (IR). The valid range proportion (VRP) can be 
established using IR and the measurement range (MR), the latter being defined as the 
maximal minus the minimal observed test value (VRP = (MR - IR) / MR). 
3.3.6.2 Sensitivity and specificity of the P. pastoris expressed MVV TM-
polypeptide ELISA. 
Results obtained using the P. pastoris expressed MW TM-polypeptide ELISA for the. 
36 negative and positive reference sera were evaluated using the TG-ROC calculated 
cut-off value (Table 3.4). 
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Table 3.4 
Sensitivity and specificity values obtained of the MVV TM-polypeptide ELISA using 
the TG-ROC calculated cut-off value. 




Recombinant 30/36 83 30/36 83 
MVV -TM polXPeptide 
a TP, number of test-positive samples; PR, number of positive reference 
sera tested; TN, number of test negative samples; NR, number of negative 
reference sera tested. 
Equality of test parameters (Se=Sp=9o) is thus obtained when the cut-off de (0.256) is 
selected (Table 3.4). 
3.3.6.3 1l0<: plot 
In Figure 3.7 a ROC plot of the P. pastoris expressed MVV TM-polypeptide ELISA 
was constructed using the TG-ROC software as described in Chapter 2. In this graph 
the value of l-Spj is plotted on the x-axis (independent variable) and the value of Se.i is 
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Figure 3.7 ROe plot of the P. pastoris expressed MVV TM-polypeptide specific 
ELISA. 
The ROe graph is a plot of all the sensitivity/specificity paIrs resulting from 
continuously varying the decision threshold over the entire range of results observed. 
In each case, the ROe plot depicts the overlap between the two distributions by 
plotting the sensitivity (or true positive fraction) versus 1- specificity (or false-positive 
fraction) for the complete range of decision thresholds. 
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3.4 DISCUSSION 
Early successes in the production of heterologous proteins were achieved using the 
well-studied bacterium Escherichia coli as a host (ltakura et al., 1977). However, as 
the nature of the recombinant proteins being expressed became more complex, other 
potential host systems were investigated. Yeast offers a number of advantages as an 
expression system. As an unicellular micro-organism, it retains the advantages of the 
bacterial systems in ease of manipulation and growth. On the other hand, yeasts 
possess a eukaryotic subcellular organisation capable of accurately processing and 
secreting many different proteins (Buckholz and Gleeson, 1991). Thus, the expression 
of a recombinant protein in yeast is often a suitable choice that combines a cost-
effective method of production with the ability to post-translationally modify proteins 
in an appropriate manner. 
In this chapter the construction of a MVV TM coding P. pastoris expression vector, 
and its use in the production of a MVV TM-polypeptide antigen. A 117-bp DNA 
fragment (Figure 3.3), coding for an antigenic TM-polypeptide region, was cloned in 
frame with the S. cerevisiae a-mating factor secretion signal (Figure 3.4). The 89 
amino acid S. cerevisiae prepro alpha mating factor leader sequence (Figure 3.2) has 
been effective at directing secretion of several proteins from P. pastoris (Vedvick et 
al., 1991; Clare et al., 1991). To maximise the stability of foreign protein production 
clones, expression vectors are integrated into the P. pastoris genome. A major factor 
which determines the state (autonomous versus integrated) as well as location of a 
plasmid in P. pastoris transformed cells is whether sequences homologous to the P. 
pastoris genome were present on the plasmid (Cregg et al., 1985; Cregg and Madden, 
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1987). The recombinant pPIC9 vector was linearized at the AOX1 5' sequences to 
stimulate single-crossover type integration events. A subset of resulting His + colonies 
are deleted at AOX1 which forces them to rely on the transcriptionally weak AOX2 
gene (Cregg et al., 1993). These clones metabolise methanol at a reduced rate which 
can be used to selectively screen for clones with such a specific phenotype (see Section 
3.2.8). 
These AOX disrupted clones were also shown to express higher levels of foreign 
protein than wild-type hosts, e.g. J3-galactosidase (Tschopp et al., 1987a), invertase 
(Tschopp et al., 1987b) and hepatitis B surface antigen (Cregg et al., 1987). However, 
despite the fact that both clones A2 and B 11 exhibited reduced growth on methanol 
containing medium, poor expressed protein concentrations were obtained. 
Furthermore, the presence of the integrated 117-bp MVV TM-polypeptide coding 
DNA fragment has been confirmed by PCR analysis (Figure 3.5), excluding the 
possibility of non-recombinant mutant clones. P. pastoris clones with multiple copies 
of heterologous gene expression cassettes have been described (Romanos et al., 1991). 
Clones harbouring multiple copies often, but not always, synthesise significantly higher 
levels of protein (Sreekrishna et aI., 1989; Clare et al., 1991; Barr et al., 1992). Thus 
the possibility exists that both clones A2 and B 11 contain only a single gene copy of 
the MVV TM-polypeptide coding sequence which could explain the low expression 
levels obtained. 
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Large-scale expression oftheMVV TM-polypeptide was performed in the presence of 
Pefabloc® SC, a non-toxic serine protease inhibitor (Section 3.2.12). Omitting such a 
protease inhibitor has not led to an increase in expressed protein (data not shown), 
indicating that the low expression levels were not due to the presence of proteases in 
the medium. However, optimum expression levels were repeatedly obtained after 72 h 
of methanol induction (Section 3.3.4) for both clones A2 and Bll, as revealed by 
ELISA reactivity (Section 3.2.10). 
Since the expected molecular weight of the secreted MVV TM-polypeptide is only 
about 5 kDa, an N-terminal histidine-coding tag was incorporated during the PCR 
amplification (Table 3.1). Subsequent protein purification was based on the selectivity 
of the Ni-NT A resin for proteins with an affinity tag of six consecutive histidine 
residues- the 6x His tag. This technology allowed for one-step purification of the 
recombinant protein under mild elution conditions. Furthermore, the 6x His affinity tag 
is much smaller than most other affinity tags e.g. GST, and is known to be poorly 
immunogenic in most species and therefore did not require removal by protease 
cleavage. The short 6x His tag has also been shown to be readily expressed in yeast 
(Bush et al., 1991; 10hnson et al., 1993; Ridder et al., 1995), and also in other host 
systems such as: bacteria (Le Grice and Grtininger-Leitch, 1990), mammalian cells 
(Sporeno et al., 1994) and baculovirus (Waeber et al., 1993). 
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Purification of the MVV TM-polypeptide was done under non-denaturing conditions in 
the presence of a protease inhibitor (PM SF} and the reducing agent mercaptoethanol 
(Section 3.2.12). The addition of mercaptoethanol to the loading buffer reduced 
background due to cross-linked proteins. This has been reported to be important 
especially when purifying proteins which contain cysteine residues (Janknecht et al., 
1991), as is the case with the expressed MVV TM-polypeptide. Background 
contamination can arise from proteins that contain mUltiple consecutive histidines, and 
thus have some affinity for the Ni-NT A resin or proteins that associate non-specifically 
with the 6x His tagged protein. 
As a result of the low expression levels and small expected molecular weight of the P. 
pastoris expressed MVV TM-polypeptide, visualisation of the recombinant protein 
using conventional electrophoretic and Western blot analysis proved to be 
unsuccessful. ELISA remained the only means of detecting and arbitrarily quantifying 
the MVV TM-polypeptide. 
Evaluation of the diagnostic performance of the MVV TM-polypeptide was 
accomplished using a panel of 36 confirmed negative and positive sera, respectively, 
selected on the criteria as described in Section 2.2.11 and evaluated using the two-
graph operating characteristic (TG-ROC) as described in Section 2.2.12. The receiver 
operating characteristic (ROC) analysis is the standard method to demonstrate the co-
variation of Se and Sp. ROC plots for diagnostic tests with perfect discrimination 
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between negative and positive reference samples would pass through the co-ordinates 
(0; 1) (Se = Sp = 100%). This was the situation using the E. coli GST -TM-p25 
expressed antigen (Figure 2.3.3 .2). Consequently, the area under such ROC curves 
would be 1.0, irrespective of the difference between the greatest observation in the 
negative and the lowest observation in the positive sample. The ROC curve for the P. 
pastoris expressed TM-polypeptide (Figure 3.3.6.3) demonstrates all valid pairs of Se 
and Sp which can be obtained when the cut-off value is changed systematically over 
the complete measurement range. In TG-ROC, Se and Sp are plotted as dependent 
variables separately against the assumed cut-off value as the independent variable 
(Figure 3.6). Numerically, one obtains estimates for the cut-off do which can be used if 
an equal Se and Sp is desired and the resulting test parameter (Se = Sp = 80) is 
indicated. Therefore, a selected cut-off (do = 0.225) (Table 3.3) yielded equal Se and 
Sp of 83%, (Table 3.4), respectively. This cut-off was obtained using the non-
parametric programme option as the distribution of the negative and positive reference 
data (Table 3.2) showed a deviation from normal (see Section 2.2.12 for criteria of a 
normal distribution). If a conventional cut-off value (mean plus two-fold standard 
deviation of the negative reference sample) was considered, a Se of about 36% and an 
Sp of about 97% would result. 
TG-ROC can also be used to define "intermediate" test results by establishing two 
alternative cut-off values. The TG-ROC algorithm warrants an Se and Sp of at least 
95% (as preselected), for results outside the IR. The IR for an ideal test can be 
assumed to be equal to zero because the upper limit of IR is less than the lower limit as 
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was the case with the GST -TM-p25 ELISA (Table 2.3). The valid range proportion 
(VRP) would then be 1.0 and both Se and Sp would be greater than or equal to 95%. 
For the TM-polypeptide ELISA, in contrast, TG-ROC indicates a positive IR (Table 
3.3) and VRP = 0.696. It can therefore be concluded that only those individual test 
results that fall within 69.6% of the variable range (MR.) can be diagnosed with an 
accuracy of greater than 95%. 
A further significant aspect of TG-ROC is that it can be used to compare diagnostic 
tests. VRP and eo are independent of any selected cut-off value and, therefore, ideal 
parameters for test comparison. Comparison of the above two parameters for the 
GST-TM-p25 ELISA (VRP = 1.0~ eo = 0.995) (Table 2.3) and the TM-polypeptide 
ELISA (VRP = 0.696; eo = 0.833) (Table 3.3) confirmed the superior diagnostic ability 
of the GST-TM-p25 antigen compared to the TM-polypeptide. 
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CHAPTER 4 
DEVELOPMENT OF A RAPID WHOLE BLOOD 
AGGLUTINATION TEST FOR MAEDI-VISNA VIRUS 
4.1 INTRODUCTION 
An accurate assessment of the animal health situation of the livestock in a country is a 
necessary condition for implementing disease eradication or control programmes. In 
many developing countries, it is difficult for veterinary services to establish a full list of 
the diseases prevalent in the country, due to constraints such as insufficient numbers of 
field veterinarians and a lack of well-equipped diagnostic laboratories. As a result, 
developing countries are often aware of only a small proportion of disease outbreaks. 
It is therefore difficult to make an accurate assessment of the geographical distribution 
and relative importance of diseases. 
Recent advances in biotechnology may help to resolve these problems through the 
development of rapid field diagnostic assays. These field diagnostic assays could help 
diagnosticians to make rapid and appropriate decisions in the event of a disease 
outbreak. The ideal field diagnostic assay should be sensitive and specific but should 
also be easy to use by unskilled persons and require minimal equipment. 
A novel rapid immunoassay system has been described (see Figure 1.13), which allows 
the detection of circulating antibodies in whole blood (Kemp et al., 1988; Wilson et 
al., 1991). This test uses endogenous erythrocytes as indicator cells and a monocIonal 
anti-erythrocyte Fab' fragment conjugated via the inter heavy chain cysteines to a 
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synthetic peptide epitope. The erythrocytes are coated with the peptide antigen by 
adding Fab'-peptide conjugate to a drop of blood. If circulating antibodies to the 
peptide are present the erythrocytes visibly agglutinate. This test format is carried out 
in whole blood with minimal sample handling and a result is obtained within two min. 
The central feature of this whole blood immunoassay system lies in a monoclonal 
antibody against a glycophorin epitope that is present on all red blood cells of the 
particular species being tested. In this chapter the isolation and characterization of a 
monoclonal antibody that recognises all sheep erythrocytes but does not cross-react 
with other mammalian erythrocytes (Boshoff et al., 1996b), its coupling to MVV 
specific antigen and its use in the rapid diagnosis of Maedi-Visna virus in sheep 
(Boshoff et al., 1996c). 
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4.2 MATERIALS AND METHODS 
4.2.1 Preparation of whole sheep blood cells for immunisation 
Freshly drawn sheep blood was washed three times in 0.15 M NaCI by centrifugation 
at 1000 x g. The washed red blood cells were diluted in 0.15 M NaCI to a final 10% 
(v/v) suspension. 
4.2.2 Immunisation of mice 
Balb/c mice were immunised intraperitoneally with 100 III of a 10% (v/v) sheep red 
blood cell suspension in 0.15 M NaCl. Two weeks later, a booster immunisation of 
similar dose was given followed by a further two immunisations at three-weekly 
intervals, the last one, three days prior to fusion. 
4.2.3 Monoclonal antibody production 
Hybridomas were produced by fusing the splenocytes of an immune mouse with NSO 
myeloma cells using PEG 1500 essentially following the method of Kohl er and Milstein 
(1975). Briefly, the spleen of an immune mouse was aseptically removed and prepared 
as described by Galfre and Milstein (1981). Splenocytes were obtained by 
homogenisation of the spleen with a scalpel and forceps followed by trituration in a 
sterile syringe as described before (Boshoff et al., 1992). After sedimentation of spleen 
debris, the cells were transferred to sterile 10 mI centrifuge tubes, washed twice with 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with NaHC03 (3.7 gIl), 
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sodium pyruvate (1 mM).' amphotericin B (1 J.lglml) and penicillin streptomycin 
mixture (10 IU/ml and 10 J.lg/ml, respectively) and finally resuspended in the same 
medium. NSO cells were harvested, washed once and resuspended in DMEM with 
supplements. The cells were fused by adding a total of 1 ml 40% polyethylene glycol 
(pEG) (Boehringer Mannheim MW 1500) dropwise over a period of 60 seconds. The 
suspension was incubated for 90 sec at 37°C, and 5 ml serum free DMEM was added 
dropwise over a period of 5 min with constant swirling. The suspension was left at 
room temperature for 10 min before transfer to 195 ml DMEM containing supplements 
as above, 10% fetal calf serum [Highveld Biological (Pty) Ltd], 5% horse serum 
[Highveld Biological (pty) Ltd] and 1 x HAT [hypoxanthine (100 J.lM), aminopterin 
(0.4 J.LM) and thymidine (16 J.lM)] (Flow Laboratories). The mixture was distributed 
into the wells of 96-well microtitre plates (Cel-Cult, Sterilin, Middlesex, UK.) at 
100 J.lI per well and incubated in a humidified incubator at 5% CO2 air ventilation. 
Medium was changed every 3 days, aminopterin was excluded after one week and after 
the second week hypoxanthine and thymidine were omitted as well. The wells were 
monitored microscopically for colony growth and culture supematants of the 
hybridomas were screened according to their ability to agglutinate sheep erythrocytes. 
Hybridomas secreting reactive antibodies were subcloned by limiting dilution. This 
process was repeated until all of the subclones secreted the desired antibody ensuring 
monoclonality. 
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4.2.4 Screening of bybridoma supernatants 
Erythrocyte suspensions were prepared by washing as described above. The washed 
erythrocytes were diluted in 0.15 M NaCI to give a 2-5% (v/v) suspension. Fifty JlI of 
suspension was placed in a small test tube to which 50 JlI of hybridoma supematant 
was added. The contents of the tube were mixed well and centrifuged immediately at 
(1000 x g, 15 sec, RT). Following centrifugation, 20 JlI of a 30% (w/v) BSA solution 
(Miles, Il, U.S.A.), was added to the tube and gently shaken to resuspend the cells and 
agglutination recorded. The degree of agglutination was scored on a scale of 1 + to 4+ 
by evaluation of agglutination with the naked eye. The weakest agglutination detected 
in this manner was scored as 1 + and strong complete clumping of erythrocytes as 4+. 
4.2.5 Ascites production 
Ascitic fluid was produced by injecting 106 viable hybridoma cells per mouse into the 
peritoneal cavity of pristane (tetramethylpentadecane) (Aldrich Chemical Company, 
Milwaukee, WI) primed Balb/c mice (0.5 ml/mouse, 7 days prior to hybridoma 
inoculation). After a few days, when swelling of the abdomen could be observed, the 
ascites fluid was tapped off using a wide gauge needle. The fluid was clarified by 
centrifugation (3000 x g, 10 min, RT) and stored at -20°C. 
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4.2.6 Purification of mAb JC6 using protein A affinity chromatography 
Chromatography of antibody solutions over a protein A bead column is one of the 
most · effective and widely used methods for purifying . antibodies from many types of 
crude preparations (Goding, 1978; Langone, 1982). Protein A coupled to preswollen 
agarose (5 ml) (Boehringer Mannheim), was packed into a plastic column and washed 
with five column volumes ofTS-buffer (50 mM Tris-HCI, 150 mM NaCI, pH 8.0). The 
pH of the ascites preparation was adjusted to 8.0 by adding 1/10 volume of 1.0 M Tris 
(pH 8.0) before being passed through the protein A agarose column. Any unbound 
material was removed by washing the agarose beads with ten column volumes of TS-
buffer. IgG1 was subsequently eluted with 5 ml 0.1 M sodium citrate pH 6.0, followed 
by IgG2a elution with 5 ml 0.1 M sodium citrate pH 5.0 and finally IgG2b and IgG3 with 
5 ml 0.1 M sodium citrate pH 3.0. 
4.2.7 CHARACTERIZATION OF AN ANTI-SHEEP GLYCOPHORIN 
SPECIFIC MONO CLONAL ANTIBODY, JC6 
4.2.7.1 Epitope characterization ofmAb JC6 
The nature of the epitope recognised by mAb JC6 was examined by selective chemical 
and enzymatic treatment of erythrocytes immobilized on polyethyleneimine (PEI) 
coated 96-well microtitre plates (Greiner, Germany). Microtitre plates were prepared 
by coating PEI (MW 50000, Sigma) at a concentration of 20~g!ml in PBS pH 7.2 for 
30 min (F. Green, personal communication). The plates were washed with 50 mM 
Tris-HCI, 150 mM NaCI pH 8.0 containing 0.05% Tween 20 (TST) buffer, rinsed with 
water and vacuum dried. Washed sheep erythrocytes were diluted to a 0.2% (v/v) 
99 
suspension in 0.15% NaCI and dispensed at 100 J.lllwell onto the PEI coated microtitre 
plates. After 30 min at room temperature the erythrocyte suspension was flicked out 
and the microtitre plate wells washed three times with TST. Plates prepared in this 
manner were coated with a visible monolayer of sheep erythrocytes which were lysed 
by inverting the plate and centrifuging (1000 x g, 30 sec, RT). Stroma prepared in this 
manner was free of haemoglobin when tested for pseudo-peroxidase activity. 
4.2.7.2 Trypsin treatment of immobilized sheep erythrocytes 
The microtitre ELISA plates were coated as described above. The immobilized sheep 
erythrocytes were incubated with trypsin EC 3.4.21.4 (Sigma) at 100 J.lglml in PBS pH 
7.2 (5 J.lglwell) (Arya et al., 1994). In the controls, no trypsin was added to antigen-
coated wells. The plates were incubated for 1 h at 37°C. After washing three times 
with TST, the non-specific sites were blocked for 1 h at room temperature using TS 
containing 5% (w/v) skimmed milk powder. Blocked wells were filled with a 111000 
dilution of ascitic fluid in 5% (w/v) skimmed milk powder in TS (50 J.lllwell) and 
incubated for another h at room temperature. The plates were washed with TST and 
subsequently incubated with rabbit anti-mouse IgG (H+L)-peroxidase conjugate, 
diluted 11200 in TS, followed by a final TST washing and colour development with 50 
J.lllwell substrate solution of Q-phenylenediamine (10 mg) and urea-hydrogen peroxide 
(8 mg) in 10 ml sodium citrate buffer (0.1 M, pH 4.5). The reaction was stopped with 
0.5 M sulphuric acid (100 J.lllwell) and read at 492 nm in an automatic ELISA plate 
reader (Titertek Multiskan, Flow laboratories, McLean, Va.). 
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4.2.7.3 Period ate treatment of immobilized sheep erythrocytes 
Sodium metaperiodate-mediated oxidation of erythrocyte carbohydrate residues was 
performed using 20 mM sodium periodate in 50 mM sodium acetate (pH 4.5) for 1 h 
as described before (Woodward et al., 1985). Wells without sodium periodate 
treatment served as controls. The effect of periodate oxidation on the epitope 
recognised by mAb JC6 was tested by ELISA as described above. 
4.2.7.4 Neuraminidase treatment of immobilized sheep erythrocytes 
Neuraminidase EC 3.2.1.18 from Clostridium perfringens (Boehringer Mannheim) was 
dispensed at 0.1 units/lOO J-lllwell in PBS pH 7.2 supplemented with 100 J-lg/ml BSA. 
Wells were incubated at 37°C for 1 h and washed with TST. Untreated wells were 
used as controls. The specificity of mAb JC6 for sialic acid was examined by ELISA as 
described before. 
4.2.7.5 Isotyping 
The heavy-chain subclass of monoclonal antibody JC6 was determined by double 
immunodiffusion (Ouchterlony) and ELISA using goat anti-mouse IgM, IgGI, IgG2a, 
IgG2b and IgG3 specific unlabeled and HRP-Iabeled antibodies (Sigma Chemical 
Company, St. Louis, MO). 
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4.2.7.6 Western Blot Analysis 
a) Epitopes detected by mAb, JC6 
Sheep erythrocyte membranes were prepared by cold hypotonic lysis according to the 
procedure of Dodge et al. (1963). The membranes were repeatedly washed with cold 
5 mM phosphate buffer until all haemoglobin was removed. The washed membranes 
were solubilized in an equal volume of 0.1 M Tris-HCI (pH 6.8}.containing 5% (w/v) 
SDS, 5% (v/v) 2-mercaptoethanol, 20% (w/v) sucrose, 2 mM 
phenylmethylsulphonylfluoride (PMSF) and 0.001% (w/v) bromophenol blue. SDS-
P AGE was performed on the solubilized erythrocyte membranes using the 
discontinuous buffer system of Laemmli (1970), with a 4% (w/v) acrylamide stacking 
gel on a 12.5% (w/v) acrylamide separating gel using a Bio-Rad slab-gel apparatus. 
One hundred micro grams of membrane protein was applied per lane. Electrophoresis 
was performed for 2 h at 25 mA/gel. Separated sheep erythrocyte proteins were 
electrophoretically transferred from the gel onto nitrocellulose membranes (Schleicher 
and Schuell, Keene, u.K.) using the method of Hampson et al. (1989). The 
nitrocellulose membranes were blocked for I h in 5% (w/v) skimmed milkITS solution, 
washed in TST, then incubated for 4 h at room temperature with mAb JC6 ascitic fluid 
diluted 111000 in 5% skimmed milkITS. The membranes were then washed three times 
with TST and incubated for I h at room temperature with rabbit anti-mouse IgG 
(HRP)-labelled conjugate diluted 11200 in 5% skimmed milkITS. After washing twice 
with TST and a final wash with TS, the nitrocellulose membranes were immersed in 
freshly prepared substrate (60 mg 4-chloro-I-naphtol, Bio Rad) in 20 m1 cold methanol 
mixed with 100 m1 cold TS buffer containing 60 ,.d of30% hydrogen peroxide. 
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b )Total carbohydrate and protein detection 
To detect the carbohydrate and protein moieties of the separated membrane proteins 
blotted onto the nitrocellulose membranes, a Digoxigenin-glycanlprotein Double 
Labelling Kit from Boehringer Mannheim was used. This involved the specific 
oxidation of the polysaccharides of a glycoprotein with period ate followed by covalent 
coupling of the Digoxigenin hydrazide hapten to the newly created aldehyde groups. 
The protein fraction of the glycoprotein and nonglycosylated proteins were labelled 
according to the principle of the Digoxigenin-Glycanl protein Detection Kit in which a 
succinimide ester conjugated fluorescein hapten is coupled to all free amino groups. 
The specifically introduced haptens were detected in a reaction using anti-digoxigenin-
POD and anti-fluorescein-AP antibody conjugates, respectively. 
4.2.8 F(ab)2 fragment production 
The mono clonal antibody, JC6, directed specifically against sheep erythrocytes was 
purified as described in 4.2.5. The purified antibody was subsequently dialyzed against 
100 mM phosphate buffer, pH 6.9. F(ab)2 fragment production was essentially as 
described by Parham et al. (1982). Papain (EC 3.4.22.2) (Boehringer Mannheim) was 
diluted to 30 unitslml (activity was taken to be that stated by the manufacturer) with 
100 mM phosphate pH 6.9 consisting of 50 mM L-cysteine. The enzyme was allowed 
to activate for 30 min at 37°C prior to desalting on a PD-lO (Sephadex G-25) desalting 
column (Pharmacia) equilibrated in 100 mM phosphate, pH 6.9. The papain containing 
fractions free of cysteine, as determined by reaction with 5,5'- dithiobis (2-nitrobenzoic 
acid) DTNB (Riddles et al., 1983), were pooled and the concentration of papain 
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determined using an A2so for a 0.1% w/v solution as 2.5 (determined by diluting a 
solution of papain of known concentration and measuring the absorbancy at 280 nm). 
To each 1 mg of antibody, 1 unit of papain was added and the digestion allowed to 
proceed for 2 h whilst shaking at 37°C. The reaction was stopped by the addition of 
iodoacetamide to a final concentration of 30 mM. The digested antibody was dialyzed 
against a 50 mM Tris-HCI, 150 mM NaCI, pH 8.0 (TS-buffer), solution and the F(ab)2 
fragment separated from residual intact IgG and Fc fragments using a protein A 
column. The F(ab)2 fragments were concentrated using a Microcon-l00 filter (Amicoll, 
Beverly, U.S.A.) as prescribed by the manufacturers. 
4.2.9 F(ab)z fragment reduction 
The purified F(abh fragments were suspended in 1 ml, 100mM phosphate, pH 6.0 
containing 5mM EDT A. This solution was added to a vial containing 6 mg of 2-
mercaptoethylamine-HCI (2-MEA, 50 mM final concentration) (pierce Chemical 
Company, U.S.A.) and incubated for 90 min at 37°C. The solution was allowed to cool 
to room temperature and desalted using a PD-l 0 desalting column (pharmacia Biotech, 
U.S.A.) equilibrated in 100 mM phosphate, 150 mM NaCI, 0.05% w/v NaN3, pH 6.8, 
buffer. The void volume fraction containing the reduced Fab' fragments was added to 
solid DTNB to a final concentration of 25 mM and after mixing for 15 mill, a final 
concentration of30 mM iodoacetamide was added and allowed to react in the dark for 
a further 15 min. The Fab'-TNB-Ac (acetamide blocked Fab'-TNB) was desalted as 
described above in 100 mM phosphate, 150 mM NaCI, 0.05% w/v NaN3 pH 6.8 buffer 
before any unreacted F(abh fragments were removed using a microcon-l00 filter 
(Amicon, Beverly, U.S.A.) and collecting the Fab'-TNB-Ac flow through. 
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4.2.10 Peptide reduction 
A 16-mer synthetic peptide analogue of gp40 (785-800) RFKDNCTWQQWEEEIE 
designed from the published SA-OMVV sequence (Querat et al., 1990) was purchased 
from Neosystem, France. The peptide was solubilized at a final concentration of 
10 mg/ml in 0.18 M acetic acid by pre-wetting the lyophilized peptide with 20 JlI of 0.9 
M acetic acid, then making up to volume with de-ionised, distilled water. The solution 
was aliquoted and stored at -70°C. Peptide gp40 (785-800) was reduced as described 
by Kemp et al. (1988) with some modifications. The solubilized peptide was diluted to 
2 mg/ml with 0.1 M Tris-HCI, 1 mM EDTA, 4 M guanidine hydrochloride, 50 mM 
DTT, pH 8.0 and reduced for 30 min at room temperature. The peptide was 
maintained in reduced form by the addition of an equal volume of 10 mM HCI and 
desalted using a Biogel P2 (Bio-Rad, Richmond, CA) column, eluted with 10 mM HCI. 
The reduced peptide was recovered by lyophilization. 
4.2.11 Quantification of antibody and peptide concentrations 
The concentrations of antibody and peptide solutions were determined by comparing 
the absorbancy of the solution at 280 nm with the absorbancy of a standard 0.1% wlv 
solution at 280 nm [A28o(0.1 % w/v)]. For antibodies a relative [A28o(0.1 % w/v)] value 
of 1.4 was calculated, by accurately weighing and making up a standard solution of 
lyophilised antibody which was extensively dialyzed against water and using 
comparative colour development with the Lowry protein assay (peterson, 1983). In the 
case of the peptide solution, the relative concentration was obtained by making up a 
standard peptide solution in 180 mM acetic acid, making up several dilutions so that 
the absorbencies at 280 nm were between 0.1 and 1.0, and calculating the standard 
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[A28o(0.1% w/v)]. Free sulthydryls present on the peptide were determined by Ellman's 
test, diluting the peptide in excess DTNB, measuring the absorbancy at 412 nm, and 
calculating the moles ofTNB2- released using E412nm = 14 150 Ml cm-1 (Riddles et al., 
1983). Similarly, the amount of TNB in modified antibody fragments was determined 
as described for the peptide by the addition of excess DTT to the antibody fragments 
and calculating the increase in absorbancy measured at 412nm. 
4.2.12 Peptide conjugation and conjugate purification 
The reduced peptide was added in molar TNB2- ratios of 10:1 peptide to antibody 
fragment. The reaction was stopped after 1 min by adding iodoacetamide to a final 
concentration of30 mM and incubation for 15 min at room temperature. Any reformed 
F(ab)2 fragments were removed using a Microcon-lOO filter. The Fab'-peptide 
conjugate flow-through was concentrated using a Microcon-30 filter. The conjugate 
was suspended at 10 J,lllrnl in PBS/azide pH 7.4, containing 0.5% fish gelatin (Sigma) 
and stored at 4°C. 
4.2.13 Peptide ELISA 
The synthetic gp40 peptide was dissolved in 100 mM NaHC03 buffer pH 9.6 and 
coated on 96-well microtitre plates (Greiner, Germany) at 9 J,lg per well (Kwang and 
Torres, 1994). The peptide was dried by evaporation overnight at 37°C. The peptide 
was tested for reactivity against a panel of confirmed negative and positive anti-MVV 
sera. 
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4.2.14 Red cell agglutination assay 
For the agglutination assay, Fab'-peptide conjugate solution (30 J.lI) was added to a 
well of a plastic tray containing 10 J.lI confirmed negative or positive serum containing 
10 J.lI of packed erythrocytes from a MVV negative sheep. The agglutination mixture 
was swirled for 2 min and agglutination assessed visually according to a scale of 0 
(negative) to 4+ (strong positive) (Wilson et al., 1991). 
4.2.15 Electrophoresis and Western blot analysis of antibody fragments 
Antibody fragments and conjugate were analyzed using SDS-P AGE (Laenunli, 1970) 
under non-reducing conditions with Coomassie blue G-250 staining and by 
immunoblotting (Towbin et al., 1979; Wilson et al., 1994). 
4.2.16 Data analysis 
For the 10 negative and 10 positive serum samples tested the following were calculated 
(Griner et al., 1981; Hardy, 1991): 
Sensitivity: the ratio of true positives divided by total positives (sum of true positives 
and false negatives) 
Specificity: the ratio of true negatives divided by total negative results (sum of true 
negatives and false positives). 
Predictive value-positive: the ratio of true positives divided by total positives (sum of 
true and false positives). 
Predictive value-negative: the ratio of true negatives divided by the total negatives 
(sum of true and false negatives). 
False positive rate: 100 minus specificity. 
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False negative rate: 100 minus sensitivity. 
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4.3 RESULTS 
4.3.1 Selection of monoclonal antibodies 
Hybridomas producing anti-sheep erythrocyte antibodies were screened for 
agglutination. Selection was on the basis of their ability to strongly agglutinate all 
sheep erythrocytes. Clone JC6 gave a convincing 4+ agglutination score and was found 
to be of the IgG1 isotype. 
4.3.2 Reactivity of mAb JC6 to erythrocytes from different sheep breeds 
Erythrocytes from six different sheep breeds were screened by agglutination with mAb 
JC6. All blood samples from the different breeds reacted with mAb JC6 (Table 4.1), 
suggesting a conserved and ubiquitous nature of the epitope recognised by mAb JC6. 
Table 4.1 Agglutination strength of anti-sheep red blood cell monoc1onal antibody 
tested against various sheep breeds. 












"Total number tested> 200 
4.3.3 Nature of the epitope recognised by mAb JC6 
The chemical nature of the epitope recognised by mAb JC6 was investigated by 
treating the immobilized sheep erythrocytes with trypsin, sodium meta-periodate and 




















Figure 4.1 Effect of trypsin, sodium periodate and neuraminidase treated immobilized 
sheep erythrocytes on the reactivity of mAb JC6. ELISA values were obtained from 
two repeats, each comprising 32 measured ELISA plate wells per data point (i.e. 
n=64). 
Trypsin treatment had little effect on the reactivity of mAb JC6 whereas periodate 
treatment significantly reduced the affinity of mAb JC6 for the immobilized sheep 
erythrocytes, suggesting a carbohydrate nature of the epitope recognised by mAb JC6. 
Immobilized sheep erythrocytes were subsequently treated with neuraminidase as 
described in 4.2.7.4. Neuraminidase treatment significantly reduced the reactivity of 
mAb JC6 for the immobilized sheep erythrocytes. Neuraminidase is known to 
specifically remove sialic acid residues present on glycoproteins (Suttajit and Winzler, 
1971), hence the suggestion that the epitope recognised by mAb JC6 consists of sialic 
acid dependent moieties. Figure 4.2, lane 2 shows the reactivity ofmAb JC6 to the 





Figure 4.2 Western blot analysis of sheep erythrocyte membrane proteins immobilized 
onto nitrocellulose membranes. Lane 1: Western blot profile using mAb JC6; Lane 2: 
Total carbohydrate profile labelled with Dig-hydrazide hapten after periodate oxidation 
of the immobilized sheep erythrocyte membranes; Lane 3: Total protein profile of the 
immobilized sheep erythrocyte membranes following reaction with a succinimide ester 
conjugated fluorescein hapten. 
Four distinct bands can be identified at 135 kDa, 70 kDa, 50 kDa and 25 kDa, 
respectively. Lane 3 is a total carbohydrate stain of sheep erythrocyte membranes 
clearly indicating that the majority of the carbohydrate is in the region of 50 kDa. In 
addition, the bands recognised by mAb JC6 (lane 2) tend to correlate with 
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carbohydrate stained bands (lane 3). Lane 4 shows a total protein profile of sheep 
erythrocyte membranes. 
4.3.4 Fab'-peptide conjugate preparation 
The preparation of the anti-erythrocyte Fab'-peptide conjugate was illustrated in Figure 
1.13. It is based on the procedure developed by Brennan et al. (1985) for the 
preparation of bispecific antibodies. The SDS-PAGE gel analysis of the product at 
each stage of the anti-sheep erythrocyte Fab'-peptide conjugate preparation is shown in 
Figure 4.3. 
Figure 4.3 12.5% SDS-PAGE of samples taken at various stages of conjugate 
preparation. Lane 1: Intact antibody; Lane 2: F(ab)2 fragment; Lane 3: Fab'-TNB-Ac· 
Lane 4: Fab'-peptide conjugate. ' 
The intact anti-sheep erythrocyte antibody (lane 1) was subjected to pre-activated 
papain digestion to produce F(ab)2 fragments (lane 2) (parham et al., 1982). This was 
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necessary as pepsin digestion was found to produce a variety of intennediate products 
due to indiscriminate digestion of the intact antibody (results not shown). The F(ab)2 
fragments were reduced to Fab' fragments (lane 3) using 2-mercaptoethylamine (2-
MEA). The reduced hinge sulfhydryls were protected with 5, 5' -dithiobis-(2-
nitrobenzoic acid) (DTNB) (Brennan et al., 1985). Addition of reduced gp40 (785-
800) peptide displayed the TNB to give an Fab'-peptide conjugate. Any residual 
sulfhydryl groups were blocked with iodoacetamide. This is an important step as it 
prevents disulfhide exchange and the rapid loss of peptide from the Fab' fragment. 
Purification of each resultant product indicated in Figure 4.3 described in 4.2.12 
eliminated all non-reacted or chemically refonned protein fragments. These purification 
steps proved to be vital to prevent any non-specific agglutination reactions. 
4.3.5 Evaluation of the test 
The agglutination reaction was scored visually on a scale of 0 (negative) to 4+ (strong 
positive) (Wilson et al., 1991). The test was perfonned using the conjugate at 
10 Jlglml in PBS/azide supplemented with 0.5% fish gelatin. The choice of peptide 
used was based on ELISA results published earlier (Kwang and Torres, 1994) showing 
the antigenic nature of this particular peptide which represents an immunodominant 
region of the envelope gp40 protein of the Maedi-Visna virus. The Fab'-peptide 
conjugate was tested against 10 MVV seropositive and 10 seronegative serum samples 
as ascertained using the gp40 (785-800) peptide ELISA as reference assay. The 
agglutination strength observed for each sample is shown in Table 4.2. 
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Table 4.2 Red cell agglutination results and peptide inhibition tests on 10 seronegative 
and 10 seropositive MVV serum samples. 
Negative Agglutination Result Positive Agglutination Result 
...... ~p.!.~ .............. ~~ .. ~p.!!~~ .... ~~~.~~.~p.~~~ ................... ~!Ep.!.~ ................ ~~.~p.~.~~ ......... ~.~~~.~J?~.~~ ............... . 
1 0 0 11 2+ 0 
2 0 0 12 2+ 0 
3 1+ 1+ 13 3+ 1+ 
4 0 0 14 2+ 0 
5 0 0 15 1+ 0 
6 0 0 16 2+ 0 
7 0 0 17 0 0 
8 1+ 1+ 18 2+ 0 
9 0 0 19 2+ 1+ 
10 0 0 20 2+ 0 
The specificity of each agglutination reaction was assessed by the addition of 50 ~g 
free gp40 (785-800) peptide to each serum sample and compared with the 
agglutination strength observed without the presence of free peptide (Table 4.2). 
Negative samples 3 and 8 showed false positive agglutination reactions which could 
not be . inhibited by the addition of free peptide. Positive sample 17 showed a false 
negative agglutination reaction. Furthermore, positive samples 13 and 19 could not be 
totally inhibited by the presence of free peptide indicating that some of the 
agglutination observed is due to peptide non-specific reactions. Although the 10 
positive serum samples were shown to be highly reactive towards the gp40 (785-800) 
peptide on ELISA, only relatively weak agglutination reactions were observed with the 
Fab'-peptide conjugate. Sensitivity, specificity and predictive value positive/negative 
and false positive/negative rate values for the gp40 (785-800) peptide ELISA and Fab'-
peptide agglutination assay are summarized in Table 4.3. 
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Figure 4.4 Visual agglutination ofa MVV seronegative and seropositive 
whole blood sample, respectively. The Fab'-peptide conjugate was added 
to each sample and scored after 2 min. 
Table 4.3: Sensitivity, specificity, predictive value positive/negative and false 
positive/negative rate values for the gp40 (785-800) peptide ELISA and the 
whole blood agglutination test. 
........................ ~.~.Y. ........................................ ~~~~!~Y.!!Y. ........... §.~!E.£~.o/. ............. ~.~ ........... ~~ .......... ~~ ............ ~ ..... . 
gp40 peptide ELISA 100% 100% 100% 100% 0% 0% 
whole blood agglutination 90% 80% 83% 90% 20% 10% 
PVP: Predictive value positive; PVN: Predictive value negative; FPR: False positive rate; FNR: False 
negative rate. 
4.3.6 Western blot analysis of discrepant samples 
The two false positive samples (3 and 8) and the false negative sample (17) (see Table 
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Figure 4.5 Western blot analysis of discrepant agglutination samples: False positive 
samples [3 and 8] (lanes 1 and 2, respectively), and false negative sample [17] (lane 3) 
as revealed in Table 4.2. 
Figure 4.5 shows that neither sample 3 (lane 1) nor 8 (lane 2) reacted with the Fab'-
peptide conjugate, further substantiating the notion that the false agglutination that 
occurred was due to peptide non-specific reactions. However, sample 17 reacted 
strongly with the Fab'-peptide conjugate (Figure 4.5, lane 3) confirming its specificity 
towards the coupled peptide. The reason for its inability to produce agglutination, 
however, is not clear. 
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4.4 DISCUSSION 
Mammalian erythrocyte membrane proteins carry numerous cell surface antigens that 
have been studied extensively (Hamaguchi and Cleve, 1972). The proteins of 
erythrocyte membranes from various species have been compared by SDS-P AGE 
followed by protein and carbohydrate staining. Although a marked similarity between 
the protein profiles is evident amongst the various animal species, differences in 
periodic acid Schiff (PAS) staining bands corresponding to glycophorin have been 
noted (Tillack et al., 1972; Fujita and Cleve, 1975). Glycophorins are present in 
abundance and carry a large portion of the total carbohydrate on the erythrocyte 
membranes. Comparison of the complete amino acid sequences of human glycophorin 
A (Tomita et al., 1978), porcine glycophorin (Honma et al., 1980) and horse 
glycophorin (Murayama et aI., 1981) show that there is no significant homology 
between the sequences of the extracellular amino-terminal glycosylated domains. This 
is in line with the contention that glycophorin is a species-specific antigen. 
We have described the isolation and characterization of a mAb, JC6, which recognises 
a sheep specific membrane protein, possibly glycophorin, that shows no reactivity 
towards human, bovine, rabbit and goat erythrocytes (data not shown). The epitope is 
present on all sheep breeds tested (Table 4.1). 
Selective chemical and enzymatic treatments revealed that trypsin treatment of the 
epitope had little effect on its recognition by mAb JC6 (Figure 4.1). This was 
surprising but could be due to the absence of a trypsin site or more likely the 
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inaccessibility of such a cleavage site as a result of attached polysaccharide chains 
(Furthmayr and Marchesi, 1983; Wasniowska et al., 1992; Wasniowska et aI., 1993). 
In contrast, periodate oxidation reduced the ability of mAb JC6 to bind to the 
immobilized sheep erythrocytes emphasising the carbohydrate nature of the recognised 
epitope (Figure 4.1). In addition, neuraminidase treatment of the immobilized sheep 
erythrocytes destroyed the recognition of mAb JC6 indicating that sialic acid residues 
are required to constitute the epitope recognised by mAb JC6 (Figure 4.1). Western 
immunoblot analysis, Figure 4.2 (lane 1), showed four separate bands appearing at 
25 kDa, 50 kDa, 70 kDa and 135 kDa, respectively. This might indicate that two 
distinct monomeric forms of glycophorin are present at 25 kDa and 70 kDa, 
respectively, or that they can exist as dimers. The majority of carbohydrate is 
associated with a 50 kDa protein (Figure 4.2, lane 2), although different protein bands 
were visualised over a wide range of molecular masses (Figure 4.2, lane 3). It is 
possible that the major sialoglycoprotein of sheep erythrocytes exists as a dimer 
configuration at 50 kDa. 
Current immunoassays available for the diagnosis of MVV infection are complex, 
require several washing steps and expensive instrumentation. Technician error and 
subject variability further limit the utility of these techniques as field diagnostic assays. 
In addition, it has been shown that stored sera may give occasional false positive 
results in ELISAs (Gruffydd-Jones et al., 1988). 
The simplicity of the whole blood agglutination assay, which requires no technical 
manipulation, is an appealing veterinary field test as previously described for the feline 
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immunodeficiency virus (Wilson et al., 1994~ del Fierro et al., 1995). In this chapter 
the development and evaluation of a similar assay format for the detection of Maedi-
Visna virus in sheep is described. The principle of the endogenous agglutination assay 
is illustrated in Figure 1.13. 
Possible deactivation of the antigen binding portion of an antibody that occurs when 
cross-linking whole antibodies, is avoided by selective enzymatic cleavage to obtain 
F(ab)2 fragments and subsequent coupling of the antigenic peptide at the antibody 
hinge region. This approach, first applied by Nisonoff and Rivers (1961), also has the 
advantage of removing the hydrophobic Fc region which is . implicated in non-specific 
binding (Boscato and Stuart, 1988) and numerous effector functions including 
complement binding and interactions with rheumatoid factor and heterophile antibodies 
(Gosling, 1990~ Kato et al., 1979). By removing the Fc region and using Fab' 
fragments the likelihood of obtaining a false positive agglutination through non-specific 
interactions is reduced. 
The MVV agglutination test was assessed by direct comparison with the corresponding 
MVV gp40 (785-800) peptide ELISA (Table 4.2). Kwang and Torres (1994), showed 
that the above mentioned synthetic peptide is able to detect the presence of MVV 
antibodies in 96% of infected sheep. Only previously tested MVV seropositive and 
seronegative samples as confirmed by the gp40 (785-800) peptide ELISA were used to 
evaluate the performance of the agglutination test. The purpose of this study was to 
demonstrate the feasibility of the autologous red cell agglutination test for antibodies 
to MVV and not to attempt a comprehensive trial. Thus, the results are a preliminary 
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assessment of the sensitivity and specificity of the MVV agglutination test. Although 
the number of sheep used for the study was limited by the amount of prepared 
conjugate and free peptide used to inhibit specific agglutination, 10 seronegative and 
10 seropositive samples were tested. The red cell agglutination test had a sensitivity of 
90% and a specificity of 80% (Table 4.3). The calculated predictive value positive and 
predictive value negative (Table 4.3), which are a reflection of the reliability of a test, 
indicate limitations in the use of the agglutination assay compared to the gp40 peptide 
ELl SA. 
The principal contributor to false positive · results was the auto agglutinating nature of 
mono clonal antibody JC6. The whole blood agglutination test system is a multi-step, 
expensive and error-prone process based on the chemical conjugation of Fab' 
fragments to peptides. Mixing the anti-red cell Fab' fragment with peptide could 
produce a number of theoretical reaction products, some of which are bivalent and 
cause autoagglutination of the red blood cells. This is because mouse IgG1 contain 
three inter-heavy chain cysteines (Adetugbo, 1978; Sakano et al., 1979) at the hinge 
region of the molecule. Thus, up to three TNB2. per Fab' may have been substituted 
with three possible reaction products, namely · Fab'-monopeptide, Fab'-dipeptide and 
Fab'-tripeptide. If it is assumed that the coupling process is random then the presence 
of Fab'-peptide-Fab', Fab' dimer- or F(ab)2 and dipeptide cannot be excluded. The 
filtration purification method employed after each step to remove such unwanted by-
products proved to be unsuccessful to fully block background agglutination. Western 
blot analysis of samples 3 and 8 (Figure 4.5) further substantiated the notion that the 
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false agglutination observed was more likely due to agglutinating antibody fragments 
than other non-specific reactions such as heterophile antibodies. 
This by-product formation also emphasizes the need for a suitable purification method 
not only to separate Fab' from F(ab)2 fragments but also Fab'-TNB from Fab'-peptide 
fragments. Since the Fab' and Fab'-peptide fragments are chemically closely related, 
affinity chromatography using a monoclonal antibody which is specific for the peptide 
can be used to separate the species. The inability of the filtration purification method to 
separate Fab' from Fab'-peptide might explain the overall low agglutination strength 
observed for the 10 seropositive samples (Table 4.2). The presence of contaminating 
Fab'-TNB fragments with the Fab'-peptide conjugate solution led to an underestimation 
of the actual Fab'-peptide conjugate concentration present. A final concentration of 
10 J..lg/ml conjugate was used which implies that the actual working concentration of 
the conjugate was less than 10 J..lg/ml. Increasing the conjugate concentration, 
however, led to an increase in the percentage of false positive results obtained (results 
not shown). The inability of sample 17 to produce a positive agglutination result can 
possibly be attributed to an insufficient conjugate concentration to detect all positive 
samples. Sample 17, however gave a strong positive reaction with the Fab'-peptide 
conjugate using Western blot analysis (Figure 4.5) confirming its reactivity towards the 
conjugated peptide. 
The current format for whole blood diagnostic reagent relies on the use of single-chain 
Fv fragments (scFv) with equivalent binding specificity to the parent monoclonal 
antibody (Lilley et al., 1995). The possibility of producing a stable scFv fragment of 
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monoclonal antibody JC6 holds promise for developing a rapid immunoassay in ovine 




Several serological diagnostic tests have been developed to detect Maedi-Visna virus 
(MVV) specific antibodies, but only the agar gel immunodiffusion (AGID) test and the 
whole-virus (WV) ELISA proved to be of practical value. In addition to poorly defined 
sensitivity and specificity, a major problem for both the AGID test and WV ELISA is 
the general low quality and high expense associated with viral test antigen production. 
Recently, recombinant transmembrane protein (TM) and major capsid protein p25 
were used as solid phase antigens in enzyme-linked immunosorbent assays. It has also 
been reported that antibody against p25 appears prior to the TM protein, although the 
TM immunoassay has proved to be the most accurate and sensitive at the subclinical 
and overt clinical disease stages. The implication at the practical level is that a MVV 
serological assay should include both the p25 and TM proteins to be able to detect 
early infected animals as well. 
In this thesis the cloning and expression of antigenic regions of the Maedi-Visna virus 
and their use as diagnostic reagents is described. Recent advances in biotechnology 
have made available many options for expressing and producing protein products. 
Historically, the bacterial expression system has been the most extensively used 
heterologous expression system and has resulted in the accumulation of a large body of 
literature. Therefore, gene fragments coding for the major core p25 protein and TM 
protein were cloned in frame with the pGEX-2 prokaryotic expression vector. The 
pGEX series of vectors permit the expression of recombinant proteins in Escherichia 
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coli as fusion proteins with glutathione S-transferase. Unique high affinity binding sites 
incorporated into the fusion partner enables rapid one-step purification of the GST 
fusion protein. The p25 and TM protein products were shown to be antigenically 
authentic, both as separate proteins or as combined expressed fusion protein. Since no 
absolute method ("gold standard") for the diagnosis of subclinical MVV infection 
exists, authenticity of the above mentioned proteins could only be defined by its 
reactivity with control antisera from pathologically negative and positive animals, 
respectively. 
Comparative analysis of the ELISA performance of the expressed GST -p25, GST -TM 
and combined expressed GST -TM-p25 proteins has shown the superior diagnostic 
ability of the combined expressed GST-TM-p25 fusion protein. Since only sheep older 
than three years of age were included in the study, a predominantly anti-TM antibody 
titre was expected. This was reflected by the GST -TM and p25 commercial assay 
giving a 100% and 87% sensitivity, respectively. The conclusion can therefore be made 
that the ideal serologic assay for MVV should contain at least these two antigens since 
any individual serum may react with only one of them during the course of infection, 
but is believed to be unlikely not to react with either of them. 
Often, bacterial cells tend to accumulate the heterologous protein as an insoluble 
product, concentrating the protein within the cell in inclusion bodies. Subsequent use 
of denaturing conditions to solubilize such fusion proteins may render the fusion 
protein resistant to affinity purification. Furthermore, the MVV TM protein is known 
to be hydrophobic, causing protein aggregation despite the fact that a truncated 
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version of the TM protein was expressed. As a result, modification of the induction 
conditions and solubilization procedures of the expressed fusion proteins were 
adopted. Induction of protein expression at 20°C and subsequent solubilization of the 
expressed protein with the non-denaturing detergent N-Iauroylsarcosine circumvented 
the protein aggregation problem. However, the possibility of non-specific reactions 
remained, as reflected by the slight drop in specificity observed for the GST -TM assay 
compared with that of the commercial p25 and GST-TM-p25 assay. Nevertheless, the 
recombinant pGEX expressed fusion protein ELISAs had cost and performance 
advantages over the conventional methods for anti-MVV antibody detection. 
The solubility problems encountered with the pGEX expression system prompted the 
search for an alternative expression system. The Pichia pas/oris yeast expression 
system offered several advantages in the production of recombinant proteins. Among 
these advantages, the high-level secretion of the recombinant protein into the culture 
medium promised to simplify product recovery and purification. However, limited 
success was achieved in an attempt to express the MVV TM-polypeptide in high 
yields. A possible explanation might be that only a single gene copy of the TM-
polypeptide was integrated into the P. pas/oris genome. In addition, the small expected 
size of the expressed TM-polypeptide made detection by SDS-PAGE and Western-blot 
analysis even more problematic. Although the above mentioned attempts proved to be 
in vain, evaluation of the expressed and purified TM-polypeptide as a diagnostic 
reagent, could be effected by ELISA. 
125 
No diagnostic test exhibits perfect operating characteristics under all conditions. The 
traditional approach to improve the accuracy of diagnosis is to develop new tests with 
superior sensitivity and specificity. An alternative, yet rarely used approach, is to 
improve existing tests by altering the cut-off value that distinguishes infected 
individuals from uninfected individuals. For any given serological test, sensitivity and 
specificity are determined by the cut-off value. Two steps are essential for the selection 
of cut-off values in any quantitative diagnostic test. Firstly, a statistically appropriate 
method has to be chosen that permits valid extrapolations from observed test results of 
reference samples to the situation when the test is applied to the target population. 
Secondly, a cut-off value has to be selected which differentiates the two 
subpopulations of infected and non-infected controls with defined operating 
characteristics. In many applications of serodiagnostic tests it may be appropriate to 
select cut-off values with equal weights on sensitivity and specificity. This thesis 
presented the use of a modified receiver operating characteristic (ROC) analysis 
programme which depicted sensitivity and specificity separately versus the selected 
cut-off value. The construction and application of this method, including the definition 
of "intermediate" test results and the "valid range proportion" are exemplified using 
data from the pGEX and the P. pastoris expressed recombinant antigens, respectively. · 
New diagnostic techniques are evolving rapidly and each provides new opportunities 
which can be beneficial to the study and treatment of veterinary diseases. In many 
cases these techniques are developed in human medicine, but can easily be adapted to 
veterinary disease problems. One such recent advance has been the preparation of 
antibody conjugates and their application to autologous red blood cell agglutination 
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assays. The conjugate consisted of a peptide, representing an immunodominant portion 
of MW, coupled to the anti-sheep red blood cell mono clonal antibody. When added 
to whole blood, red blood cells are bound by the antibody domain, effectively coating 
the erythrocytes with antigen. In the absence of antibodies to the coupled antigen, no 
agglutination is expected, but cross-linking can occur if antibodies are present. Within 
a limited number of 10 seronegative and 10 seropositive samples the MVV autologous 
whole blood agglutination test had a sensitivity of 90% and a specificity of 80%. The 
principal contribution to the false positive agglutination reactions was attributed to the 
auto agglutinating nature of mono clonal antibody JC6. This is due to the fact that 
despite the fact that monovalent Fab' fragments were used, reformation of some Fab' 
fragments still occurred. A possible improvement in the manufacturing of antibody 
conjugates may result from recent explorations in the genetic engineering of antibody 
molecules (Winter and Milstein, 1991). Bacterial expression products representing 
antibody fragments linked to a protein or peptide have significant advantages over 
chemical methodologies for the formation of such antibody-based reagents (Hudson et 
al., 1992). 
Molecular biology, in its relatively short history, has dramatically altered out 
perception of infectious diseases and the paths that should be followed to improve the 
health of animals. Steady progress has resulted in a number of practical applications to 
the study and diagnosis of infectious diseases of veterinary importance. Work 
presented in this thesis illustrates the use of recombinant DNA and monoclonal 
antibody technology as applied to the serological diagnosis of MVV. Undoubtedly, 
these technologies will present many new opportunities for diagnosis and the 
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prevention of a wide range of diseases and as such their impact is certain to grow over 
the years to come. 
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APPENDIX 1 
lOX One-Phor-AII ButTer PLUS: 
100 mM Tris acetate, 100 mM magnesium acetate, 500 mM potassium acetate (PH 
7.5) 
Reagents for transformation of E. coli 
SOB medium 













To prepare SOB medium," combine tryptone, yeast extract, NaCI and KCI in water. 
Autoclave. Prepare a 2 M stock of Mg2+, comprised of IM MgCh and IM MgS04. 
Filter sterilise through a 0.22 J..lm membrane. Prior to use, combine the media with the 
magnesium solution. Add 100 J..lg/ml ampicillin. Final pH is 6.8-7.0. Store at 4°C, and 
use within two weeks. To prepare as a solid medium, add 1.2-1.5% agar . 
. TFB (Standard Transformation ButTer) 
Use double-distilled water for preparation of all solutions . 
................ ~~s.~.~.~ ............................. ~2~~0..~!~E ............................. ~.~!!~! .. £2!!£~.~~E~~!2!! ............. . 









20 ml of 0.5 M stock 
(pH6.3) 





** Equilibrate a 0.5 M solution of MES (2-[N-morpholino]-ethone sulfonic acid) to 
pH 6.3 using concentrated KOH. Filter sterilise the solution through a 0.22 J..lm 
membrane. Store in aliquots at -20°C. 
To prepare the TFB, add the salts as solids, then filter the solution through a 0.22 J..lm 
membrane. Final pH should be 6.2 ± 0.10. Pour aliquots into sterile flasks and store at 
4°C. TFB is stable for about one year. 
SOC medium: Identical to SOB, but contains 20 mM glucose in addition to listed 
reagents. To prepare SOC medium, combine tryptone, yeast extract, NaCI and KCI in 
water. Autoclave. Prepare a 2 M stock of glucose. Filter sterilise through a 0.22 J.lm 
membrane. Cool medium then add glucose to a final concentration of 20 mM. Prepare 
a 2 M stock of Mg2+, comprised of 1 M MgCh and 1 M MgS04. Filter sterilise 
through a 0.22J..lm membrane. Prior to use, combine the media with the magnesium 
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solution. Add 100 J.lglml ampicillin. Final pH is 6.8-7.0. Store at 4°C, and use within 
two weeks. To prepare as a solid media, add 1.2-1.5% agar. 
2XYTMedium 
........... ~.~~g~~! .................. !:.~~~~~.~2~~~.~!E~!~2~ ..... . 
Tryptone 16 gIl 
Yeast extract 10 gIl 
NaCI 5 sf! 
Dissolve above ingredients in 900 ml of distilled H20. Adjust the pH to 7.0 with 
NaOH. Adjust the volume to 1 liter. Sterilise by autoclaving for 20 minutes. To 
prepare as a solid medium, add 1.2-1.5% agar. 
2X YT -G Medium 
........ ~~~g~E! ................. !:~~~L~2~~~~!E~!~2~ .... . 
Tryptone 16 gIl 
Yeast extract 10 gIl 
NaCI 5 gf! 
Dissolve above ingredients in 800 ml of distilled H20 . Adjust the pH to 7.0 with 
NaOH. Adjust the volume to 900 ml. Sterilise by autoclaving for 20 minutes. Once the 
medium has cooled, aseptically add 100 ml of a sterile 20% glucose solution (final 
concentration 2% glucose). To prepare as a solid medium, add 1.2-1.5% agar. 
2X YT-G Medium + 100 J.lglml ampicillin 
See protocol for 2X YT -G medium, above. At the same time as the glucose is added, 
also add 1 ml of a 100 mglml ampicillin stock solution (final concentration J.lglml). 
Ampicillin stock solution 
Dissolve 100 mg of the sodium salt of ampicillin in 4 ml of water. Sterilise by filtration 
and store in small aliquots at -20°C. 
Reagents for small-scale isolation of plasmid DNA (Alkaline Lysis Method) 
Solution I: 100 mM Tris-HCI (PH 7.5), 10 mM EDTA, 400 J.lg of heat-treated 
RNAse I1ml. 
Solution IT: 0.2 M NaOH, 1 % (w/v) SDS. 
Solution ID: 3 M potassium, 5 M acetate. To prepare 100 ml, mix 60 ml of 5 M 
potassium acetate, 11.5 ml of glacial acetic acid and 28.5 ml of distilled water. 
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pGEX Sequencing Primers 
Primer Sequence (5' - 3') Nucleotide location 
3' pGEX CCGGGAGCTGCATGTGTCAGAGG 1020-998 
AOXl Sequencing Primers 
Primer Sequence (5'- 3') Nucleotide location 
5' AOX1 GACTGGTTCCAATTGACAAGC 855-875 
3' AOX1 GCAAATGGCATTCTGACATCC 1347-1327 
Media recipes for the growth and expression of recombinant proteins in P. 
pastoris 
Stock Solutions 
lOX YNB (Yeast Nitrogen Base) 
Dissolve 134 g of yeast nitrogen base (YNB) without amino acids in 1000 ml of water 
and filter sterilise. Store at 4°C. Stable for one year. 
500X B (Biotin) 
Dissolve 20 mg biotin in 100 ml of water and filter sterilise. Store at 4°C. Stable for 
one year. 
lOOX H (Histidine) 
Dissolve 400 mg of L-histidine in 100 ml of water and filter sterilise. Store at 4°C. 
Stable for one year. 
lOX D (Dextrose) 
Dissolve 200 g ofD-glucose in 1000 ml of water. Autoclave for 15 minutes. Stable for 
one year. 
lOX M (Methanol) 
Mix 5 m1 of methanol with 95 m1 of water. Filter sterilise and store at 4°C. Stable for 
two months. 
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lOX GY (Glycerol) 
Mix 100 m1 of glycerol with 900 m1 of water. Sterilise by autoclaving. Store at room 
temperature. Stable for one year. 
lOOX AA (Amino Acids) 
Dissolve 500 mg each of L-glutamic acid, L-methionine, L-Iysine, L-Ieucine and L-
Isoleucine in 100 m1 of water. Filter sterilise and store at 4°C. Stable for one year. 
1 M potassium phosphate butTer, pH 6.0 
Combine 132 m1 of 1 M K 2HP04, 868 ml of 1 M KH2P04 and confirm that the pH = 
6.0 ±O.l (if the pH needs to be altered, use phosphoric acid). Sterilise by autoclaving 
and store at room temperature. Stable for one year. 
Growth 
YPD 
Dissolve 109 of bacto yeast ~xtract and 20 g of 12eptone in 900 m1 of water (include 
20 g ofbacto agar if making YPD plates) and autoclave for 20 minutes. Add 100 m1 of 
10X D. Makes 1 liter. The liquid medium is stored at room temperature. YPD plates 
are stored at 4°C. Stable for several months. 
Transformation 
RDB (Regeneration Dextrose Base) 
Dissolve 186 g of sorbitol and 20 g of agar in 700 ml of water and autoclave. Cool and 
maintain in a 45°C water bath. Add a prewarmed (45°C) mixture of stock solutions: 
100 m1 of 10X D, 100 m1 of 10X YNB, 2 ml of 500X B, 10 m1 of 100X AA and 88 m1 
of sterile water. Makes 1 liter. After mixing, pour the plates immediately. The plates 
are stored at 4°C and should last for several months. 
RD (Regeneration Dextrose-top agar) 
Composition is the same as RDB, except use only 109 of agar. Maintain the 
autoclaved solution in a 60°C water bath prior to addition of prewarmed mixture of 
stock solutions. During transformation, use as a molten solution at 45°C. 
Screening 
MD (Minimal Dextrose) 
Combine 800 m1 of autoclaved water with 15 g agar and autoclave. Coolautoclaved 
mix to about 60°C and then add: 100 ml of 10X YNB, 2 ml of 500X B, and 100 m1 of 
lOX D. Makes 1 liter. After mixing, pour the plates immediately. MD stores well for 
several months at 4°C. 
MM (Minimal Methanol) 
Combine 800 m1 of autoclaved water with 15 g of agar and autoclave. Cool the 
autoclaved mix to 60°C and then add: 100 ml of 10X YNB, 2 m1 of 500X B, and 100 
m1 of 10X M. Makes I liter. After mixing, pour the plates immediately. MM stores 
well for several months at 4°C. 
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Protein Expression 
BMGY (ButTered Minimal Glycerol-complex Medium) 
Combine 109 of yeast extract, 20 g peptone and 700 ml water and autoclave. Let it 
cool to room temperature then add the following and mix well: 100 ml 1 M potassium 
phosphate buffer, pH 6.0, 100 ml10X YNB, 2 ml 500X B, 100 ml 10X GY. Store at 
4°C. The shelflife of this solution is approximately two months. 
BMMY (ButTered Minimal Methanol-complex Medium) 
Combine 109 of yeast extract, 20 g of peptone and 700 ml of water and autoclave. Let 
it cool to room temperature then add the following and mix well: 100 ml 1 M 
potassium phosphate buffer, pH 6.0, 100 ml 10X YNB, 2 ml 500X B, 100 ml10X M. 




DNA SEQUENCE OF GST-TM-p25 (COM2) AND ITS COMPARISON 
WITH THE SA-OMVV SEQUENCE 
TMPORTION 
40 50 60 
AAGCTATAGTCGATAGAATGATGCT 
.................................................. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 
OLVSAOMV.DNA AAGCTATAGTCGATAGAATGATGCT 
8180 8190 8200 ~ 8210 8220 
70 80 90 .100 110 120 
MVVCOM2.DNA CTATCATGAATTGGATTGTTGGCATTATCAACACTATTGTGTAACCTCTACTAGAACAGA 
.......................................................................................... .. ............................ .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 
OLVSAOMV.DNA CTATCATGAATTGGATTGTTGGCATTATCAACACTATTGTGTAACCTCTACTAGAACAGA 
8230 8240 8250 8260 8270 8280 
130 140 150 160 170 180 
MVVCOM2.DNA AGTAGCACAATATGTAAATTGGACAAGATATAAGGATAATTGCACATGGCAGCAGTGGGA 
........................................ .. .............................................................................. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 
OLVSAOMV.DNA AGTAGCACAATATGTAAATTGGACAAGATATAAGGATAATTGCACATGGCAGCAGTGGGA 
8290 8300 8310 8320 8330 8340 
190 200 
MVVCOM2 . DNA AGAAGAGATAGAGCAACACGAGGCA· 
.................................................. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 
OLVSAOMV.DNA AGAAGAGATAGAGCAACACGAGGCA 




APPENDIX 2 (CONTINUED) 
DNA SEQUENCE OF GST-TM-p25 (COM2) AND ITS COMPARISON 
WITH THE SA-OMVV SEQUENCE 
p25PORTION 
820 830 840 850 
230 
:GTATGAAAGAAGGGC 
.............................. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 
GTATGAAAGAAGGGC 
860 870 240 250 260 270 280 290 MVVCOM2.DNA TACACGAAAAACAGGAGGATAAAGAAAAGAAGGTAGAACAACTCTACCCAAACTTGGAAA :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: OLVSAOMV.DNA TACACGAAAAACAGGAGGATAAAGAAAAGAAGGTAGAACAACTCTACCCAAACTTGGAAA 880 890 900 910 920 930 300 . 310 320 330 340 350 ~COM2.DNA AACACAGAGAAGTGTATCCTATTGTAAATTTGCAGGCTGGAGGGAGAAGTTGGAAAGCGG ........................................................................................................................ .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. JLVSAOMV.DNA AACACAGAGAAGTGTATCCTATTGTAAATTTGCAGGCTGGAGGGAGAAGTTGGAAAGCGG 940 950 960 970 980 990 360 370 380 390 400 410 ~C9M2.DNA TAGAGTCAGTGACATTCCAGCAGCTGCAAACAGTAGCAATGCAGCATGGACTTGTGTCCG ........................................................................................................................ .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. )LVSAOMV.DNA TAGAGTCAGTGACATTCCAGCAGCTGCAAACAGTAGCAATGCAGCATGGACTTGTGTCCG 1000 1010 1020 1030 1040 1050 420 430 440 450 460 470 fVVCOM2.DNA AGGATTTTGAAAGACAATTAGCATATTATGCCACTACATGGACAAGCAAAGATATATTAG . ." - . 
' . . .. . . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. )LVSAOMV.DNA AGGATTTTGAAAGACAATTAGCATATTATGCCACTACATGGACAAGCAAAGATATATTAG 1060 1070 1080 1090 1100 1110 480 490 500 510 520 530 IVVCOM2.DNA AAGTACTAGCCATGATGCCTGGAAATAGGGCGCAAAAAGAGTTAATACAGGGGAAATTAA .................................................................................. · . . . . . . . . . ~ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . )LVSAOMV.DNA AAGTACTAGCCATGATGCCTGGAAATAGGGCGCAAAAAGAGTTAATACAGGGGAAATTAA 1120 1130 1140 1150 1160 1170 540 550 560 570 580 590 rovCOM2.DNA ATGAGGAAGCAGAAAGGTGGGTAAGGCAGAATCCCCCAGGGCCAAATGTCCTTACTGTGG :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ILVSAOMV.DNA ATGAGGAAGCAGAAAGGTGGGTAAGGCAGAATCCCCCAGGGCCAAATGTCCTTACTGTGG 1180 1190 1200 1210 1220 1230 600 610 620 630 640 650 WVCOM2.DNA ATCAGATTATGGGAGTCGGACAAACAAATCAACAGGCATCGCAAGCTAATATGGATCAGG · ....................................................................... . .. . . .. . . . .. . . .. . . .. .. .. . . .. .. .. . . .. .. . . .. .. .. . .. .. . .. . .. . . . . .. . .. . .. .. .. . . . . .. . . .. .. . .. .. ·LVSAOMV.DNA ATCAGATTATGGGAGTCGGACAAACAAATCAACAGGCATCGCAAGCTAATATGGATCAGG 1240 1250 1260 1270 1280 1290 660 670 680 690 700 710 VVCOM2.DNA CAAGACAGCTTTGCTTGCAGTGGGTAATAACAGCCTTGAGATCAGTAAGACATATGTCAC · ........................................................................ . · .......................................................................... .. LVSAOMV.DNA CAAGACAGCTTTGCTTGCAGTGGGTAATAACAGCCTTGAGATCAGTAAGACATATGTCAC 1300 1310 1320 1330 1340 1350 720 730 740 750 760 770 VVCOM2.DNA ACAGACCAGGAAATCCTATGCTGATAAAACAAAAGAAT~GTGAAAGTTATGAAGATTTTA : : : : : : : : : : : : : :- : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : LVSAOMV.DNA ACAGACCAGGAAATCCTATGCTGATAAAACAAAAGAATAGTGAAAGTTATGAAGATTTTA 1360 1370 1380 1390 1400 1410 780 790 800 810 820 830 JVCOM2.DNA TAGCAAGATTGCTAGAAGCAATTGATACAGAACCCGTCACGGATCCTATAAAAACATATT : : : : : : : : : : : : :" : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : ~VSAOMV.DNA TAGCAAGATTGCTAGAAGCAATTGATACAGAACCCGTCACGGATCCTATAAAAACATATT 1420 1430 1440 1450 1460 1470 
161 
p25 PORTION (CONTINUED) 
840 --8"5"0 - . - 860 870 880 . '~8-~fo 
MVVCOM2~DNA TAAAAGTAACTCTGTCGTTCACAAATGCTAGCACAGATTGTCAAAAACAAATGGACAGAG 
...................................................... . ...................................... .. .. .. . . .. .. . .. .. .. . .. . .. .. . . . .. .. .. . .. . .. .. .. .. .. .. . .. . .. . .. .. .. .. .. . . .. .. . . .. . .. .. .. .. . .. . .. .. .. .. 
OLVSAOMV.DNA TAAAAGTAACTCTGTCGTTCACAAATGCTAGCACAGATTGTCAAAAACAAATGGACAGAG 
1480 1490 1500 1510 1520 1530 




1540 1550 1560 1570 1580 ' 1590 
960 970 
MVVCOM2.DNA TAGGATCAGAAGG 




APPENDIX 2 (CONTINUED) 
DNA TRANSLATION OF SEQUENCED GST-TM-p25 (COM2) 
1 Ser Ser Lys lIe Gly Ser Gly Ser Ala Trp lIe GIn Ala lIe Val 
1 A TCC TCC AAA ATC GGA TCT GGT TCC GCG TGG ATC CAA GCT ATA GTC 
16 Asp Arg Met Met Leu Tyr His Glu Leu Asp Cys Trp His Tyr GIn His 
47 GAT AGA ATG ATG CTC TAT CAT GAA TTG GAT TGT TGG CAT TAT CAA CAC 
32 Tyr Cys Val Thr Ser Thr Arg Thr Glu Val Ala GIn Tyr Val Asn Trp 
95 TAT TGT GTA ACC TCT ACT AGA ACA GAA GTA GCA CAA TAT GTA AAT TGG 
48 Thr Arg Tyr Lys Asp Asn Cys Thr Trp GIn GIn, Trp Glu Glu Glu lIe 
143 ACA AGA TAT AAG GAT AAT TGC ACA TGG CAG CAG TGG GAA GAA GAG ATA 
64 Glu GIn His Glu Ala Gly Ser Pro Gly lIe Arg Met Lys Glu Gly Leu 
191 GAG CAA CAC GAG GCA GGA TCC CCG GGA ATT CGT ATG AAA GAA GGG CTA 
80 His Glu Lys GIn Glu Asp Lys Glu Lys Lys Val Glu GIn Leu Tyr Pro 
239 CAC GAA AAA CAG GAG GAT AAA GAA AAG AAG GTA GAA CAA CTC TAC CCA 
96 Asn Leu Glu Lys His Arg Glu Val Tyr Pro lIe Val Asn Leu GIn Ala 
287 AAC TTG GAA AAA CAC AGA GAA GTG TAT CCT ATT GTA AAT TTG CAG GCT 
, 112 Gly Gly Arg Ser Trp Lys Ala Val Glu Ser Val Thr Phe GIn GIn Leu 
. 335 GGA GGG AGA AGT TGG AAA GCG GTA GAG TCA GTG ACA TTC CAG CAG CTG 
128 GIn Thr Val Ala Met GIn His Gly Leu Val Ser Glu Asp Phe Glu Arg 
383 CAA ACA GTA GCA ATG CAG CAT GGA CTT GTG TCC GAG GAT TTT GAA AGA 
144 GIn Leu Ala Tyr Tyr Ala Thr Thr Trp Thr Ser Lys Asp lIe Leu Glu 
431 CAA TTA GCA TAT TAT GCC ACT ACA TGG ACA AGC AAA GAT ATA TTA GAA 
160 Val Leu Ala Met Met Pro Gly Asn Arg Ala GIn Lys Glu Leu lIe GIn 
479 GTA CTA GCC ATG ATG CCT GGA AAT AGG GCG CAA AAA GAG TTA ATA CAG 
176 Gly Lys Leu Asn Glu Glu Ala Glu Arg Trp Val Arg GIn Asn Pro Pro 
527 GGG AAA TTA AAT GAG GAA GCA GAA AGG TOO GTA AGG CAG AAT CCC CCA 
192 Gly Pro Asn Val Leu Thr Val Asp GIn l+e Met Gly Val Gly GIn Thr 
575 GGG CCAAAT GTC CTT ACT GTG GAT CAG ATT ATG GGA GTC OOA CM ACA 
208 Asn GIn GIn Ala Ser GIn Ala Asn Met Asp GIn Ala Arg GIn Leu Cys 
623 AA 1:. CAA CAG GCA TCG CAA GCT AAT ATG GAT CAG GCA AGA CAG CTT TGC 
224 Leu GIn Trp Val lIe Thr Ala Leu Arg Ser Val Arg His Met Ser His 
671 TTG CAG TGG GTA ATA ACA GCC TTG AGA TCA GTA AGA CAT ATG TCA CAC 
240 Arg Pro Gly Asn Pro Met Leu lIe Lys GIn Lys Asn Ser Glu Ser Tyr 
719 AGA CCA GGA AAT CCT ATG CTG ATA AAA CAA AAG AAT AGT GAA AGT TAT 
\ 
256 Glu Asp Phe lIe Ala Arg Leu Leu Glu Ala lIe Asp Thr Glu Pro Val 
767 GAA GAT TTT ATA GCA AGA TTG CTA GAA GCA ATT GAT ACA GAA CCC GTC 
272 Thr Asp Pro lIe Lys Thr Tyr Leu Lys Val Thr Leu Ser Phe Thr Asn 
815 ACG GAT CCT ATA AAA ACA TAT TTA AAA GTA ACT CTG TCG TTC ACAAAT 
288 Ala Ser Thr Asp Cys GIn Lys GIn Met Asp Arg Val Leu Gly Thr Arg 
863 GCT AGC ACA GAT TGT CAA AAA CAA ATG GAC AGA GTG TTA GGG ACA AGA 
304 Val GIn GIn Ala Ser Val Glu Glu Lys Met GIn Ala Cys Arg Asp Val 911 GTC CAA CAG GCA TCA GTA GAA GAA AAA ATG CAA GCA TGT CGG GAC GTA 
320 Gly Ser Glu Gly Glu Phe lIe Val Thr Asp *** Arg 
APPENDIX 3 
DNA HOMOLOGY SEARCH FOR MVV TM FRAGMENT CLONED IN 
pPIC9 EXPRESSION VECTOR 
8214 8224 8234 8244 8254 826' 
OLVSAOMV.DNA AAGCTATAGTCGATAGAATGATGCTCTATCATGAATTGGATTGTTGGCATTATCAACAC~ 
X: : : : : : : : : : : : : : : : : : : : : : : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
PMVVTM.SEQ AAGCTATAGTCGATAGAATGATGCTCTATCATGAATTGGATTGTTGGCATTATCAACAC' 
40 50 60 70 80 90 
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· FIELD OF THE INVENTION 
Tms invention relates to reagents suitable for use in performing 
immunoassays for a variety of analytes in sheep blood. 
BACKGROUND OF THE INVENTION 
South African Patent 88/6937 in the name of Agen Limited 
describes various immunoassay techniques based on erythrocyte 
agglutination. It does so with reference to earlier publications and 
also discloses as the subject matter of that invention an agglutination 
assay for analytes in human blood which may be performed without 
the need for sophisticated laboratory equipment. Although that 
patent specification makes reference to the use of the technique 
disclosed therein for conducting veterinary immunoassays, it does 
not provide details of any erythrocyte binding molecule which is 
specific for but non-auto-agglutinating for non-human erythrocytes. 
It has been found by the present applicants that mono-clonal anti-
human glycophorin-A does not react with sheep erythrocytes. 
The ease with which the Agen technique may be performed under 
field conditions and the potential affordability of such an assay 
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renders the Agen technique a candidate for disease diagnosis and 
particularly for the diagnosis of viral infections such as the Maedi 
visna virus. However, the implementation of that technique in 
sheep immunoassays is clearly dependent on the development of a 
conjugate which presents on the one hand a sheep erythrocyte 
binding molecule or functionality and, on the other, the appropriate 
analyte binding molecule or functionality. Such conjugate would in 
i 
addition be required not to cause sheep erythrocytes to agglutinate 
except in the presence of the analyte for which the analyte binding 
molecule or functionality is specific. It has hitherto been unknown 
whether such sheep erythrocyte binder exists or could be developed 
and furthermore, if it could be raised, whether it would have 
sufficiently general functionality to enable it to be used for assaying 
or binding to the erythrocytes in the blood of different breeds of 
sheep. 
OBJECT OF THE INVENTION 
The development of such a general sheep erythrocyte binding 
molecule and conjugates thereof with various analyte binding 
molecules was an object of this invention and · has now been 
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achieved, thus rendering the Agen technique [and others which rely 
on erythrocyte agglutination in the presence of an analyte] useful in 
sheep immunoassays. 
DESCRIPTION OF THE INVENTION 
According to the present invention there is provided a sheep 
erythrocyte binding agent [hereinafter referred to as SEBA] which 
is characterised in that it is capable of binding to sheep erythrocytes 
without causing agglutination of such erythrocytes in the absence of 
other binding agents but causing agglutination of the erythrocytes in 
the presence of albumin. 
Further according to the invention there is provided an 
immunoassay reagent comprising a conjugate of SEBA and an 
analyte binding molecule characterised in that the reagent, when 
added to whole sheep blood, fails to cause agglutination of the 
erythrocytes in the absence of any other binding agents but causes 
agglutination in the presence of the analyte for which the analyte 
binding molecule is specific. 
- 4 -
Yet further according to the inveI?-tion there is provided an 
immunoassay reagent useful in diagnosing sheep for Maedi visna 
infection comprising a conjugate of SEBA and Maedi visna antigen 
[p.24 capsid protein]. 
Another aspect of the invention comprises a method for the in vitro 
diagnosis of infections in sheep comprising the step of using a 
conjugate as described above which contains SEBA according to the 
invention. 
EXAMPLES OF THE INVENTION 
EXAMPLE 1 
Preparation of SEBA 
The SEBA of the present invention was produced by generally 
following, with modifications, the procedure described by Kemp, 
B.E. et al (1988) Science 241:1352 for producing a human 
erythrocyte binding antibody. Sheep red blood cells obtained from 
a Dorper breed of sheep were prepared by washing the cells 3 times 
in 0,9 % saline w Iv . and resuspended in saline to 10% final 
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concentration. Balb/c mice were injec~ed intra-peritoneally with 100 
JLI of the 10% red blood cell suspension. The mice received at least 
three subsequent inoculations at three weekly intervals. Those mice 
with the strongest sheep erythrocyte agglutinating activity in their 
sera as measured by the Coombs assay [Coombs RRA et al (1987) 
J Immun Methods 101: 1] received a booster immunization before 
they were sacrificed and their splenocytes fused with NSO/1 
myeloma cells following standard hybridoma cloning procedures 
[Galfre and Milstein, C. Methods in Enzymology Academic Press 
Vol. II (1981) p.285]. Hybridoma cell supematants were tested for 
their ability to agglutinate sheep red cells using the Coombs assay. 
Isolation of SEBA 
An hybridoma clone was identified that produces monoclonal 
antibodies specific for sheep erythrocytes. This monoclonal 
antibody does not auto-agglutinate sheep erythrocytes. In the 
presence of 30 % albumin the monoclonal antibody will agglutinate 
the sheep erythrocytes. The monoclonal antibody was tested against 
the blood of more · than a hundred sheep and found to recognize an 
epitope on erythrocytes of all the sheep tested. The sheep tested 
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were of different breeds including D<?hne, Finn, Dorper, Merino 
and several different cross-breeds. 
Using a Western immunoblot technique the monoclonal ap.tibody 
was further shown to bind to a glycoprotein of the same molecular 
weight as that recognized by Jacalin, a lectin known to bind to 
glycophorin. Using anELISA technique the monoclonal antibody 
will bind to erythrocyte ghosts immobilized on microtitre plates. 
Poly-L-lysine activated plates were used and intact red blood cells 
were absorbed onto the plates, whereafter they were lysed and the 
., 
ghosts were washed in situ and used as solid phase. The binding of 
SEBA to sheep erythrocytes ghosts insolubilised in this manner was 
detected with rabbit anti-mouse IgG antibodies conjugated to a 
reporter enzyme. 
The above properties of the monoclonal antibody produced by the 
method described strongly suggests that the SEBA of the present 
invention binds to the glycophorin of the sheep erythrocytes but this 
mechanism of binding has not yet been positively proved. For the 
purposes of practical utility, however, it is unimportant whether the 
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SEBA of the invention in fact binds to the glycophorin of the sheep 
erythrocyte or to any other erythrocyte membrane protein which 
occurs commonly across different breeds of sheep. 
EXAMPLE 2 
Preparation of SEBA-MVV Ag Complex 
Generally following the principle outlined by Wilson et al (1991) 
Journal of Immunological Methods 138: 119 the Fab fragment of 
SEBA may be coupled to an immunodominant MVV antigen [p.24 
capsid protein] ,[Queratet al (1990) Virology 175 434-447. The 
gene coding for this protein may be cloned and expressed in a 
prokaryotic expression system. This complex when added to sheep 
erythrocytes containing MVV antibodies should result in the 
agglutination of the erythrocytes. In the absence of , the MVV 
specific antibodies no agglutination should take place. 
GENERAL 
It will .be appreciated that the invention of the generally applicable 
sheep erythrocyte binding agent [SEBA] of the present invention 
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opens the field for numerous . immu~ological applications of the 
invention. It also has application for confrrmation of a blood 
sample as being sheep blood as it has been shown that SEBA does 
not bind human, bovine or goat erythrocytes. It is expected that 
further investigations will not detract from applicants' conclusion 
that the SEBA of the present invention is a species specific, 
universal sheep erythrocyte binding agent which meets the 
objectives of the invention set out above. 
The invention is illustrated with regard to the ability of the SEBA-
MVV Ag conjugate to agglutinate sheep erythrocytes in the presence 
of Maedi visna antibodies. It is, however, not intended to be 
limited to such application and can be extended to conjugates with 
antigens to any other circulating antibodies or conjugates with 
antibodies to any circulating antigens. The invention thus also finds 
application in pregnancy t~sts for sheep and to confirm immunity 
following a dosing program. 
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DETECTION OF ANfIBODY TO MAEDI-VISNA VIRUS 
FIEI.D OF THE INVENTION 
TInS invention relates to immunoassay for detecting infection of sheep 
by Maedi~Visna virus and to new compounds used in such assay. 
BACKGROUND TO TIlE INVENTION 
Maedi-Visna Virus [MVV] is a non-oncogenic, exogenous retrovirus of 
the Lentiviridae subfamily. The major route of transmission of MVV is 
by horizontal spread through colostrum and milk. Animals become 
chronically infected and are characterised by increasing respiratory 
distress, persistent weight loss and a susceptibility to secondary infections. 
Since ovine lentivirus poses a worldwide threat to commercial sheep 
farming, various techniques are used for its serologic diagnosis. These 
include agar gel immunodiffusion [AGID], indirect enzyme-linked 
immunosorbent assay [ELISA], ELISA based on a double antibody 
sandwich blocking procedure and Western blot analysis. Most of these 
tests use tissue culture produced viral antigen. This source is labour 
intensive, expensive and subject to batch variation which makes it 
unsuitable for routine use. Studies have also shown that both p25 and 
TM epitopes are necessary to produce a sensitive and specific screening 
assay. This is due to the fact that the immune response tends to shift 
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during the course of disease from initiaJly being anti-p25 specific, to a 
predominantly TM specificity towards the end of the disease. 
OBJECT OF TIlE INVENTION 
It is an object of the present invention to provide a novel recombinant 
antigen suitable for use in serologic diagnosis of MVV infection in sheep 
by techniques such as enzyme-linked immunosorbent assay [ELISA] and 
modifications thereof. 
STATEMENT OF 1HE INVENTION 
According to the present invention there is provided a fusion protein 
presenting both the immunodominant core p25 and the transmembrane 
epitopes of MVV. The protein is expressed by the nucleotide bases 737 
to 1485 for the core p25 and nucleotide basis 8084 to 8357 for the 
transmembrane epitope based on the South African i~olate of Maedi-
Visna Virus [Querat et aI, Virology Vo!. 175, 1990, p. 434] . . 
The DNA sequence may obviously be modified at any position provided 
that such modification does not affect the functional integrity of the 
sequence to code for the immunogenic fusion protein of the invention. 
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According to a further aspect of the pre~ent invention there is provided 
a vector for use as a suitable expression vehicle comprising a plasmid 
including the DNA sequence as set out above. 
The plasmid is preferably the commercially available plasmid marketed 
as pGEX system by Phannacia of Sweden. 
The two DNA fragments as indicated above may be inserted at any 
position relative to each other provided the correct reading frame is 
maintained to create an expression cassette comprising both the core p25 
and the transmembrane epitopes of MVV. 
Thus, the invention essentially relates to the cloning of selected fragments 
of the MVV p25 and transmembrane [TM] proteins in the same 
expression cassette, expression of these two distinct epitopes as a single 
fusion protein in E. coli, its purification and its use in antibody detection 
assays like ELISA. 
The invention will now be described to illustrate the approach taken to 
develop an antigen to specifically and sensitively diagnose MVV infection 
serologically. 
• 4 • 
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EXAMPLE 
PCR Amplification of DNA fragments: The region coding for the TM 
and core p25 proteins of SA-OMVV were amplified as a 273-bp TM and 
748-bp core fragment respectively by the polymerase chain reaction 
[PCR]. The primers were designed according to the published sequence 
of SA-OMVV. The primers synthesized to amplify the TM and core p25 
region had BamHl and EcoRl sites at the 5' end respectively to allow 
cloning of the amplified products. The nucleotide sequences of PCR 
primer pairs used to amplify SA-OMVV DNA encoding MVV-TM and 
core p25 proteins are indicated below. 
PRIMER 
MVV TM 5' primer 
MVV TM 3' primer 
MVV core 5' primer 
MVV core 3' primer 
SEQUENCE [5' to 3'] 
5'-TCC CCC ggA TCC gAA gCT ATA gAT 
AgA-3' 
5'-TCC CCC ggA TCC TgC CTC gTg TTg 
CTC TAT-3' 
5'-TCC CCC gAA TTC gTA TgA AAg AAg 
ggC TAC AC-3' 
5'-TCC CCC gAA TTC TCC TTC TgA TCC 
TAC gTC-3' 
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After peR amplification the DNA fragments could be visualized by 
using agarose gel-electrophoresis to verify the correct size of each 
fragment. These PCR products were subsequently purified and digested 
with either BamHl or EcoRl restriction enzymes. 
CLONING OF PCR AMPLIFIED DNA FRAGMENTS 
The 273-bp TM and 748-bp core p25 fragments were then ligated 
separated and consecutively to BamHl and EcoRl digested pGex-2T 
vector, which has been treated with calf intestinal phosphatase prior to 
ligation, to prevent self ligation of vector DNA. The vector containing 
the TM and core p25 fragments was sequenced to ensure that both 
fragments retained their identity and is located correctly within the 
vector's reading frame in order to be expressed as a functional full length 
protein. All recombinant DNA techniques were performed by standard 
methods. 
EXPRESSION AND PURIFICATION OF FUSION PROTEIN 
The TM-p25 fragments are expressed in Escherichia coli as a single fusion 
protein of glutathione S-transferase, extracted and affinity purified as 
described by the manufacturers. The purity and relative molecular size 
of the recombinant protein is analyzed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis [SDS-PAGE]. 
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UflllZAll0N OF ABOVE FUSION ~ROTEIN IN EUSA 
The use of this antigen in an antibody detection ELISA has shown to 
specifically and sensitively diagnose MVV infected sheep at all stages of 
the disease. 
Clearly many variations of the invention may be devised without 
departing from the spirit of the invention. 
1 "!. • I 19 ~S Dated this l ~ day 01, H Q~ 
A ~ +h A !,)lj-ant Patent ,l\ttorney/ gent Tor, e P:-' \.. 
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